原文1--Electro-coagulation of reactive textile dyes and textile wastewater
航天器用燃料储箱防渗透内囊的研制
Electrochemistry
om
9
强电解质的Lm与c的关系
随着浓度下降,L 升高,通 m
常当浓度降至 0.001mol dm3 以下
时,L 与 m
c 之间呈线性关系。德
国科学家Kohlrausch总结的经验
式为:
L
mLeabharlann Lm(1
c)
是与电解质性质有关的常数。将直线外推至
c0
发现了一个规律:在无限稀释溶液中,每种离子独
立移动,不受其它离子影响,电解质的无限稀释摩
尔电导率可认为是两种离子无限稀释摩尔电导率之
和:
L
m
L
m,+
L
m,
这就称为Kohlrausch 离子独立移动定律。这样,
弱电解质的 查离子的
可L以 通过强电解质的 m
L
m,+
,求L m得, 。
om
The limiting molar conductivity
m m K c
400
HCl
m/(Scm2 mol-1)
300
The infinite-dilute molar conductivity
NaOH
m
m
m
200
100
The infinite-dilute molar conductivity of the cations and anions
Physical Chemistry
Electrochemistry
Electrolytic Conductivity
Adipose tissue browning and metabolic health
oduction
During evolution, animal species have been repeatedly challenged by two major threats to which they had to adapt: limited food supplies and cold temperatures. The adipose organ is an important tissue that responds to both changes in nutrient supply and ambient temperature. In higher vertebrates, white adipose tissue (WAT) stores vast amounts of nutrients as lipids in unilocular white adipocytes, which can then be released as fatty acids when food is scarce.1 Endothermic birds and mammals, more over, can maintain their body core temperature through basal metabolism or muscle-shivering thermogenesis.2 In mammals, brown adipose tissue (BAT) can both store nutrients as lipids and dissipate their energy as heat in a process called nonshivering thermogenesis.3 Classic brown adipocytes are characterized by a multi locular lipid droplet structure, high amounts of mito chondria and production of the mitochondrial brown fat uncoupling protein 1 (UCP1) which is located in the inner mitochondrial membrane (Box 1). When activated by sympathetic tone, brown adipocytes dissipate chemical energy stored as triglycerides by channelling fatty acids into β‑oxidation.3 UCP1 uncouples electron transport from ATP production, which in turn leads to controlled exothermic resolution of the electrochemical gradient and generation of heat to maintain body core tempera ture. Consequently, BAT is highly metabolically active and can be detected as hot spots of glucose uptake on PET or by MRI (Box 2). BAT activity (as determined by PET– CT) is positively corre lated with the amount of BAT,4,5 its activation status4,6 and environmental factors, such as low temperatures.7 In humans, repeated cold exposure leads
electrochimica acta参考文献格式
《Electrochimica Acta》是一本国际知名的期刊,专注于电化学领域的研究。
该期刊的参考文献格式通常遵循国际上通用的科学文献引用格式,如APA、MLA、Chicago等。
不同的学术领域和出版机构可能会有略微不同的引用格式要求。
以下是根据《Electrochimica Acta》的一般习惯,使用APA格式的一个示例:1. 期刊文章[序号] 作者. 文章标题[J]. Electrochimica Acta, 出版年份,卷号(期号): 起止页码.例如:[1] Smith, J., & Brown, R. J. (2020). Electrochemical behavior of nanostructured materials [J]. Electrochimica Acta, 331, 1-10.2. 专著[序号] 作者. 书名[M]. 出版地:出版社,出版年份:起止页码.例如:[2] Johnson, M. (2019). Modern Electrochemistry: Fundamentals and Applications [M]. New York: Springer, 217-256.3. 会议论文[序号] 作者. 论文标题[C]. 会议名称,召开地点,召开年份.例如:[3] Zhang, Y., & Wang, L. (2018). Advanced electrochemical energy storage systems [C]. International Conference on Electrochemical Science and Technology, Beijing, China.4. 学位论文[序号] 作者. 论文标题[D]. 学位授予机构,出版年份.例如:[4] Li, Z. (2021). Studies on the Electrochemical Properties of Conducting Polymers [D]. University of California, Los Angeles.5. 报告[序号] 作者. 报告标题[R]. 发布机构,发布年份.例如:[5] Roberts, A., & Chen, G. (2017). Progress report on electrochemical battery research [R]. National Institute of Standards and Technology, Gaithersburg, MD.请注意,以上仅为示例,具体的引用格式可能会根据《Electrochimica Acta》的最新要求或具体文章的出版年份有所变化。
药物分析专业英语
(dissolution) vessel 溶出杯(FTIR) 傅里叶变换红外光谱仪13C-NMR spectrum,13CNMR 碳-13核磁共振谱1ength basis 长度基准1H-NMR 氢谱2D-NMR 二维核磁共振谱:2D-NMR3D-spectrochromatogram 三维光谱-波谱图Aa stream of nitrogen 氮气流a wide temperature range 宽的温度范围absolute detector response 检测器绝对响应(值)absolute entropy 绝对熵absolute error 绝对误差absolute reaction rate theory 绝对反应速率理论absolute temperature scale 绝对温标absorbance 吸光度,而不是吸收率(absorptance)。
当我们忽略反射光强时,透射率(T)与吸光度(A)满足如下关系式:A=lg(1/T)。
absorbance noise, absorbing noise 吸光度噪音。
也称光谱的稳定性,是指在确定的波长范围内对样品进行多次扫描,得到光谱的均方差。
吸光度噪音是体现仪器稳定性的重要指标。
将样品信号强度与吸光度噪音相比可计算出信噪比。
absorbed water 吸附水absorptance 吸收率absorptant 吸收剂absorption band 吸收带absorption cell 吸收池absorption curve 吸收光谱曲线/光吸收曲线absorption tube 吸收管abundance 丰度。
即具有某质荷比离子的数量accelerated solvent extraction(ASE) 加速溶剂萃取accelerated testing 加速试验accelerating decomposition 加速破坏acceptance limit,acceptance criterion 验收限度,合格标准accidental error 随机误差accuracy 准确度。
2013血栓弹力图低分子肝素最新文献
The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit Hayden White a,Kellie Sosnowski a,Robert Bird b,Mark Jones c andConnie Solano bLow molecular weight heparins(LMWHs)are used forprevention and management of vascular thrombosis.Ingeneral,monitoring of anticoagulant activity is not required,however,certain populations may be susceptible tooverdosing or underdosing.As anti-activated factor X(anti-Xa)activity testing is not readily available,it was our aim toinvestigate the usefulness of thromboelastography(TEG;Haemoscope Corporation,Skokie,Illinois,USA)for theassessment of coagulation in patients on LMWH.All patientsadmitted to the coronary care unit on therapeutic dose ofenoxaparin were included(1mg/kg twice daily).Bloodsamples were collected4h after the morning dose ofenoxaparin once the participant had received at least threedoses.When anti-Xa activity was classified as low(0–0.5),correct(0.5–1.0)or high(>1.0),the distribution of reactiontime(R)and dose per kg showed little association with anti-Xa activity.The difference between mean R for the high anti-Xa group and the correct anti-Xa group was statisticallynonsignificant using two-sample t-test(P U0.26).A linearregression model showed no evidence of associationbetween dose per kg and anti-Xa(P U0.95).However,therewas evidence of positive association between dose per kgand R(P U0.011)wherein a10%increase in dose per kgwas associated with an increase in R of2.7(95%confidenceinterval0.6–4.7).There was no evidence of associationbetween R and anti-Xa(P U0.38).TEG was unable to beused to predict anti-Xa activity.However,TEG R wasprolonged in more than90%patients and correlated withdose of enoxaparin.As enoxaparin dose correlated poorlywith anti-Xa activity,a more global test might be necessaryto adjust dosing of LMWH in sick,hospitalized patients.Blood Coagul Fibrinolysis23:304–310ß2012WoltersKluwer Health|Lippincott Williams&Wilkins.Blood Coagulation and Fibrinolysis2012,23:304–310Keywords:enoxaparin,low molecular weight heparin,thromboelastographya Division of Critical Care,Logan Hospital and Griffiths University,Meadowbrook,Queensland,b Division of Pathology,Princess Alexandra Hospital,Woolloongabba,Brisbane and c School of Population Health University ofQueensland,Queensland,AustraliaCorrespondence to Hayden White,CICM,Logan Hospital and GriffithsUniversity,Logan Hospital,Armstrong Road,Meadowbrook,QLD4131,AustraliaTel:+61732998899;fax:+61732998376;e-mail:hayden_white@.auReceived26June2011Accepted31January2012IntroductionLow molecular weight heparins(LMWHs)are commonlyused both in prophylaxis and treatment of vascular throm-bosis.A major advantage of managing anticoagulation withLMWHs is that a weight-based dosing nomogram can beused,with no requirement for monitoring in most patients.However,in the critically ill population,in whom pharma-cokinetics may be altered by both comorbid conditions andseverity of illness,monitoring may be ensureadequate,but not over anticoagulation[1].LMWHs consist of fragments derived from unfractio-nated heparin by chemical or enzymatic depolymeriza-tion.These fragments consist of four to25distinctmolecular fragments varying in weight from4000to9000Da.LMWHs mediate their anticoagulant effectthrough antithrombin(AT).Unlike unfractionatedheparin,which produces conformational change in ATresulting in equal binding to and neutralization of acti-vated thrombin(IIa)and activated factor X,LMWHbound AT preferentially binds to Xa.The relative IIa:Xaactivity varies between the different LMWHs,depend-ing on the mean molecular weight of the drug[2].Enoxaparin,which is a relatively small4000–6000Da,demonstrates a Xa:IIaapproximately3–4:1.Therefore,theoretically,the prin-cipal(although not exclusive)anticoagulant effect ofenoxaparin is via the inhibition of Xa.Accordingly,the standard assay used for monitoringenoxaparin is via the inhibition of Xa.A number of kitsare available for measuring anti-Xa activity,althoughthere is some concern relating to interassay variability[3].Despite a lack of outcome studies,guidelines recom-mend a therapeutic anti-Xa range of0.6–1U/ml(treat-ment dose)[2].The accuracy of the assay rests on thecorrect timing of the sample in relation to dose admin-istration.Although the anti-Xa effect predominates,enoxaparin influences the coagulation cascade in otherareas including tissue factor pathway inhibitor(TFPI),direct inhibition of thrombin and platelet function and assuch,a more global assessment of coagulation mightprovide a better guide to monitoring patients in whomcomorbid conditions such as renal failure,obesity orthrombocytopenia might impact on both pharmacoki-netics and phamacodynamics[1,4,5].304Original article0957-5235ß2012Wolters Kluwer Health|Lippincott Williams&Wilkins DOI:10.1097/MBC.0b013e32835274c0Despite generally encouraging in-vitro data,a number of in-vivo studies have demonstrated a lack of consistency between LMWH dose and anti-Xa activity and anti-coagulant effect.Al Dieri et al.[6]demonstrated the coefficient of variation of area under the curve for anti-Xa and anti-IIa activities to range from22to37%for LMWHs.They noted thatfixed dosage of LMWH led to underdosage in10–13%of samples and overdosage in 5–11%,which was only partially explained by body weight and independent of the type of LMWH. Similarly,Mayr et al.[7]recorded a significant number of anti-Xa activities outside the therapeutic range while investigating the correlation between anti-Xa activity and standard doses of enoxaparin in the critically ill popu-lation.This may partially explain the poor correlation noted in some studies between anti-Xa activity and efficacy and/or safety of LMWH[6,8,9].For example, in a perioperative bridging study,Hammersting et al.[10] demonstrated that52.8%of patients were found with anti-Xa levels more than0.5U/ml despite having ceased the drug14h previously.The relationship between anti-Xa activity and clinical complications(both thrombotic and hemorrhagic)requires further elucidation[9,11,12]. Thromboelastography(TEG)measures the viscoelastic properties of blood as it clots under a low sheer stress environment,thus providing a comprehensive evaluation of the process of clot initiation,formation and stability. The purpose of this study was to evaluate the relationship between enoxaparin dose,anti-Xa activity and TEG to determine whether TEG could be used as a guide to enoxaparin therapy in the coronary care population on therapeutic anticoagulation.MethodsThis single-site,prospective,clinical trial was conducted over a period of6months to study the correlation of TEG parameters in patients on therapeutic dosage of LMWH with anti-Xa levels and other coagulation parameters. The study setting was a metropolitan coronary care unit. Ethics approval was granted by the Princess Alexandra Hospital Human Research Ethics Committee.The requirement for written informed consent was waived by the institutional review board.All patients admitted to the coronary care unit(age >18years)on therapeutic dosage of enoxaparin (1mg/kg twice daily)were included.Patients greater than 100kg received100mg twice daily and adjustments were made for renal function.Patients receiving other anti-coagulants(other than antiplatelet drugs)or enoxaparin only for prophylaxis against deep vein thrombosis were excluded.Blood samples were collected4h after the morning dose of enoxaparin once the participant had received at least three doses.Venous blood was collected by venipuncture from an antecubital vein.Venous samples were obtained simultaneously for thromboelastography,anti-Xa analysis, full blood count,coagulation profile,electrolyte and liver function test and C-reactive protein test.The TEG sample was collected into a Vacuette9NC (GBO,Kremsmunster,Austria)coagulation tube contain-ing3.2%buffered sodium citrate solution and allowed to completelyfill the tube.It was gently inverted to ensure it was adequately mixed.Processing of the sample com-menced within30min of venipuncture.Enoxaparin was quantitated using a standard chromo-genic anti-Xa activity assay(STA-Rotachrom Heparin, Diagnostica Stago,Asnieres,France)on the ACL Futura coagulation analyzer(Beckman Coulter,Sydney, Australia).The assay was calibrated using commercial calibrators(STA-calibrators HBPM/LMWH,Diagnos-tica Stago),which are referenced against a secondary standard of the01/608international standard for LMWH established in2003.TEG assays were processed using the Haemoscope TEG 5000Thromboelastograph haemostasis analyzer(Hae-monetics Corporation,Skokie,Illinois,USA).Routine machine quality control and standard calibrations were maintained.An electrical internal quality control(e-test) was performed prior to each assay.Haemoscope TEG disposable cups and pins(Haemonetics Corporation) were placed in the analyzer and prewarmed to378C. The process was initiated by transferring20m l of 0.2mol/l CaCl2into the TEG test cup to reverse citrate chelation.One millimeter of the citrated blood sample was transferred to a vial of kaolin activator and mixed by gentle inversion.A340m l aliquot of this blood sample was added to the cup and further mixed by raising and lowering the TEG pin three times before the analyzer began to automatically process the sample. Demographic data was collected including participant age,sex and primary diagnosis.The BMI was calculated. Enoxaparin dose and previous administration was detailed.Coagulation profiles,biochemistry data and anti-Xa activity were measured and recorded.The TEG measures the physical properties of the clot as it forms between the testing cup and pin.Numerous authors have described the technique[13–15].The TEG haemo-stasis analyzer provided thromboelastograph test results including reaction time(R),clot formation time(K),alpha angle,maximum amplitude,time to maximum rate of thrombus generation,maximum rate of thrombus gener-ation(TMRTG)and total thrombus generation(TTG). Statistical analysisAnalysis was performed by SAS version for Windows9.2 (SAS Institute,Cary,North Carolina,USA).Spearman’s rho was used to estimate simple correlation between continuous variables;two-sample t-test was used to com-pare continuous variables and least squares regression Thromboelastography for monitoring enoxaparin White et al.305was used to estimatelinear associations between variables with and without adjustment for potential confounders.In addition,logistic regression was used to assess potential predictors of high anti-Xa activity (anti-Xa >1.0).ResultsDescriptive statistics for the variables collected on the 50mean R for group and the correct group is statistically nonsignificant using two-sample t -test (P ¼0.26).A linear regression model shows no evidence of associ-ation between dose per kg and anti-Xa (P ¼0.95)(Fig.1).However,there is evidence of positive association between dose per kg and R (P ¼0.011)in which a 10%increase in dose per kg is associated with an increase in R of 2.7[95%confidence interval (CI)0.6–4.7].There is no evidence of association between R and anti-Xa (P ¼0.38)(Fig.2).Further regression analysis of dose per kg on other TEG parameters shows no evidence of linear association between dose per kg and K ,a,maximun amplitude,coagulation index,MRTG or thrombus generation (P >0.1for all tests);however,there is evidence of associ-ation between dose per kg and TMRTG (P ¼0.01)in which a 10%increase in dose per kg is associated with an increase in TMRTG of 3.8(95%CI 1.0–6.6).Investigation of association between anti-Xa activity and dose per kg could be confounded by timing of measure-ment (hours postdose),eGFR or creatinine levels.There-fore,regression analyses for anti-Xa activity were rerun after including hours postdose,eGFR and creatinine as covariates in the models.This effectively adjusts the effect of dose per kg on anti-Xa activity for any differ-ences in hours postdose,eGFR and creatinine between patients.The adjusted analysis shows no evidence of association between dose per kg and anti-Xa activity (P ¼0.81)or between R and anti-Xa activity (P ¼0.23).However,evidence of positive association between dose per kg and R (P ¼0.005)as well as dose per kg and TMRTG (P ¼0.003)is unchanged after adjusting for hours postdose,eGFR and creatinine.When anti-Xa is classified as low to correct ( 1.0)or high (>1.0)logistic regression shows no evidence of associ-ation with R (P ¼0.25)or dose per kg (P ¼0.26).After adjusting for hours postdose,eGFR and creatinine results were similar (R :P ¼0.18;dose per kg:P ¼0.40).anti-Xa activity recorded in 50%of our patients was the therapeutic range.Furthermore,we failed to find a correlation between the dose of enoxaparin and the anti-Xa activity.A possible explanation could relate to sampling errors,however,the mean time from dose to sampling was 4.17Æ0.5h,consistent with recommen-dations for anti-Xa sampling.A number of other patient factors can affect the relationship between the dose of LMWH and anti-Xa levels.Dose adjustment for obese patients has been the subject of much controversy.Barras et al.[12]noted that dosing regimens based on TBW led to overdosing and increase risk of adverse events,where-ras capping at a single dose of 100mg resulted in sub-therapeutic levels.However,the American College of Chest Physicians guidelines still suggest dosing based on TBW up to 144kg.We included eight patients more than 100kg [16].The mean anti-Xa level was 0.93Æ0.49,although the range of values was from 0.17to 1.86.As enoxaparin is largely excreted by the kidneys,decrease renal function will have significant effects on306Blood Coagulation and Fibrinolysis 2012,Vol 23No 4Table 1Descriptive statistics for variables collected on the 50patientsVariable N Mean SD Minimum Maximum Age 5060.9013.8633.0088.00Weight 5082.6216.9853.00127.00Height 50 1.670.11 1.47 1.93BMI5029.46 4.8121.6141.21Clexane dose 5080.6013.5060.00100.00Dose per kg 500.990.080.79 1.31INR 50 1.080.08 1.00 1.30PT 5012.160.8810.0014.00APTT 5038.44 5.6829.0056.00FIB50 6.327.75 2.4047.00Platelets 50248.6268.86134.00512.00CRP 4518.0236.940.50189.00eGFR 5078.1012.2050.0090.00Creatinine 5077.8018.3046.00120.00Anti-Xa50 1.000.280.17 1.86TEG parameters R 4914.88 6.19 5.9037.80K 50 5.24 2.95 1.8015.20a 5038.4814.1611.5064.20MA 5057.187.8340.5070.40CI 50À9.55 6.37À29.400.30MRTG 50 5.59 2.71 1.7912.99TMRTG 5018.748.750.3350.67TG50700.4391.93513.54862.44Anti-Xa,anti-Xa activity;APTT,activated partial thromboplastin time;CI,coagu-lation index;CRP,C-reactive protein;eGFR,estimated glomerular filtration rate;FIB,fibrinogen;INR,international normalization ratio;MA,maximum amplitude;MRTG,maximum rate of thrombin generation;PT,prothrombin time;TG,total thrombin generation;TMRTG,time to maximum rate of thrombin generation.Clexane (Sanofi-Aventis,Macquarie Park,NSW,Australia).Table 2R and dose per kg stratified by anti-Xa classified as high,correct or lowVariable NMeanSDMinimumMaximumanti-Xa activity [5].The mean eGFR and creatinine clearance for our study was 78.1Æ12.1and 77.8Æ18.2,respectively,and there was no association between dose per kg and anti-Xa activity after adjusting for eGFR and creatinine.However,Mismetti et al.[17]noted significant accumulation of LMWH (Nadroparin;GlaxoSmithKline,Versailles,France)in elderly health volunteers as com-pared with young volunteers,despite having normal creatinine clearance.They suggested that even a phys-iological reduction of renal function in relation to aging has measurable effects on drug clearance,although the clinical relevance of this is unknown.The average age of our patients was 61Æ14years,with the oldest being 88(anti-Xa of 1.08).Although we found a moderate nega-tive correlation between age and eGFR,(Spearman’s correlation ¼À0.48,P ¼0.0004),there was no correlation between age and anti-Xa activity.Thromboelastography has been employed for a number of years as a point-of-care tool for monitoring the coagu-lation status of patients in a variety of clinical circum-stances,including liver transplantation,cardiac bypass surgery and trauma [18–20].A number of authors have attempted to use the TEG for the rapid monitoring of anticoagulants [1,21–28].Assuming that anti-Xa activity is the gold standard for monitoring LMWH use,TEG has been compared with anti-Xa activity using a variety of endpoints including R time,alpha angle and MA and other TEG-related indices.Results,however,have been mixed with some demonstrating a good correlation with TEG,whereas others less so.For example,Klein et al.[21]examined the relationship between TEG and anti-Xa activity in orthopaedic surgery patients receivingprophylactic enoxaparin.They noted that the R value correlates significantly with peak and trough levels of anti-Xa activity (P <0.05)and concluded it could be a useful test to measure LMWH activity.Similarly,in an in-vitro study,Gerotziafas et al.[29]noted a significant correlation between tissue factor-triggered TEG R and K value and anti-Xa when comparing the effects of differ-ent concentrations of enoxaparin and fondaparinux on clotting of blood specimens taken from health volunteers.Conversely,Shinoda et al.[22]examined the usefulness of TEG for monitoring of LMWH during hemodailysis and failed to find a strong correlation between TEG R and anti-Xa activity.However,when considering the degree of dialyzer clot,they noted a good correlation with the TEG R value,whereas the anti-Xa activity correlated poorly.Similarly,Zmuda et al.[23]examined the relation-ship between TEG parameters and anti-Xa in healthy volunteers administered differing doses and types of anticoagulants.They concluded that TEG parameters did not alwayscoincide with plasma levels ofthe drug,and therefore TEG did not appear to be an appropriate modality for monitoring enoxaparin therapy.Some authors have attempted to introduce various indices of coagulation based on TEG parameters to monitor anti-Xa activity.For example,Artang et al.[24]compared anti-Xa activity to a composite TEG parameter called the throm-bodynamic ratio and noted a good correlation (using healthy male volunteers).Carroll et al.[30]created a measure called delta TEG,which represents the differ-ence between TEG R value performed with heparinase and without.They found a good correlation between anti-Xa activity (r 2¼0.806)and delta R in thrombophilicThromboelastography for monitoring enoxaparin White et al.307Fig.10.800.51.51A n t i -X a a c t i v i t y (U /m l )20.91Enoxaparin (mg/kg)1.1 1.2 1.3Comparison between anti-Xa activity and dose of enoxaparin (mg/kg)(P ¼0.95).pregnancy patients,although considerable scatter was observed at lower values.Interestingly,an ex-vivo titration of normal and thrombophilic pregnancy patient blood samples had a linear dose response of r 2more than 0.9.Thisappears to be a common occurrence wherein in-vitro studies and studies using healthy volunteers report good correlations between anti-Xa activity and TEG,whereas in-vivo studies in sick patients fail to show a correlation.We were unable to demonstrate a relationship between anti-Xa activity and any TEG parameter.Even when stratifying patients according to anti-Xa activity,mean R was no different for group with anti-Xa 0.5–1.0and more than 1.0.This lack of correlation persisted despite correcting for weight and renal function.Significantly,we did find a positive association between enoxaparin dose per kg and R (P ¼0.011)in which a 10%increase in dose per kg is associated with an increase in R of 2.7(95%CI 0.6–4.7).Furthermore,47out of 50patients receiving enoxaparin in our group demonstrated a hypocoagulable TEG with R more than 8min and a decrease in coagu-lation index,suggesting TEG is able to reflect the anti-coagulant effects of enoxaparin in coronary care patients on treatment-dose therapy.This serves to illustrate the fact that tests examining a single point of the coagulation cascade may not represent the overall coagulation picture or patient outcomes.In a randomized controlled trial comparing LMWH with heparin for deep vein thrombo-sis prophylaxis,Leizorovicz et al.[9]found anti-Xa activity correlated weakly with antithrombotic activity and did not significantly correlate with the incidence ofhemorrhage.The data,however,are inconsistent.Whereas Boneu et al.[31]and Hemker et al.[32]found anti-Xa activity to be a poor parameter to assess quality of anticoagulant effects,Levine et al.[33]found a strong correlation between anti-Xa activity and both hemor-rhage and thrombotic events.TEG is a measure of whole blood coagulation and has been shown to associate with clinical outcomes such as bleeding in cardiac and liver transplant patients.Like Coppell et al.[25],we failed to find a significant correlation between TEG parameters and anti-Xa activity,in contrast to prior in-vivo studies.There are many potential reasons for this finding.First,many studies utilize healthy volunteers to provide samples for in-vitro analysis [6,25–27].Results from these inves-tigations may not be relevant to sick patients who display altered drug metabolism through changes in drug distri-bution,biotransformation and excretion.Furthermore,sick patients may display drug interactions that are accentuated by impaired renal clearance,decreased hepatic function,electrolyte and acid–base imbalances.Second,conventional assays use platelet poor plasma,and terminate with the formation of a fibrin clot,therefore possessing a well defined end point that is easily stan-dardized.Segments of the clotting cascade are artificially isolated in these assays,and therefore they do not reflect the cellular contribution to the formation of a stable fibrin clot.Third,enoxaparin stimulates other coagulation fac-tors including inducing the release of TFPI and platelet factor 4partially neutralizing the anticoagulant activity of LMWH [11].Fourth,different methods for TEG clot308Blood Coagulation and Fibrinolysis 2012,Vol 23No 4Fig.20.51.51A n t i -X a a c t i v i t y (U /m l )21020R (min)Comparison between anti-Xa activity and R value on Thromboelastography (P ¼0.38).activation are routinely employed including kaolin and tissue factor,potentially impacting on the generalization of results[34].Lastly,although the anti-IIa effects of LMWHs are less significant the smaller the molecule,they are not absent entirely.Enoxaparin has been noted to have a Xa:IIa inhibition of approximately3–4:1.Although relatively insignificant in small doses,the effects may be more important at treatment doses.Gerotziafas et al.[26]noted enoxaparin in low concentrations had no significant effect on thrombin generation in whole blood.However,a linear correlation was found between the concentration of enoxaparin and the reduction of thrombin C max,with high concentrations almost completely abrogating throm-bin generation.Dieri et al.[6]demonstrated a23–45% (LMWH)variation in the concentration of C-domain (which represents anti-IIa activities)attained in the plasma.Fixed-dose enoxaparin led to large variations in plasma values for both anti-Xa and anti-IIa activity. Furthermore,they noted a large variation in anti-IIa levels between individuals following injection of enox-aparin with both high and low responders.As TEG is a global measure of coagulation activity,it may be more sensitive to the effects of these factors when compared with anti-Xa activity.In conclusion,we were unable to demonstrate a corre-lation between enoxaparin dose and anti-Xa activity nor could the TEG be used to predict anti-Xa activity. However,TEG R was prolonged in all but three indi-viduals and was positively associated with dose.This study was too small to evaluate the use of TEG for monitoring enoxaparin treatment in terms of clinical outcomes.However,it seems clear from this and other research that a more global test is necessary to evaluate enoxaparin dosing in sick patient populations as a number of factors other than anti-Xa activity impact on the coagulation system.AcknowledgementsH.W.and K.S.helped design the study,conduct the study,analyze the data and write the article.H.W.has seen the original study data,reviewed the analysis of the data,approved thefinal study and is the author respon-sible for archiving the studyfiles.R.B.and M.J.helped design the study,analyze the data and write the article.C.S.performed the anti-Xa assays and helped analyze the data.The authors K.S.,R.B.,M.J.and C.S.have seen the original study data,reviewed the analysis of the data and approved thefinal article.Submitted as a Research Report:This article describes human research.IRB contact information:Princess Alex-andra Hospital Human Research Ethics Committee. The requirement for written informed consent was waived by the Institutional Review Board.This article describes cohort observational clinical study.This article was screened for plagiarism using Article Checker.Link to Title Page:/pages/2854-2011-May-12.Conflicts of interestThe authors have no conflicts of interest. References1Van PY,Cho SD,Underwood SJ,Morris MS,Watters JM,Schreiber MA.Thrombelastography versus AntiFactor Xa levels in the assessment ofprophylactic-dose enoxaparin in critically ill patients.J Trauma2009;66:1509–1515;discussion15–7.2Laposata M,Green D,Van Cott EM,Barrowcliffe TW,Goodnight SH, Sosolik RC.College of American Pathologists Conference XXXI onlaboratory monitoring of anticoagulant therapy:the clinical use andlaboratory monitoring of low-molecular-weight heparin,danaparoid,hirudin and related compounds,and argatroban.Arch Pathol Lab Med1998;122:799–807.3Kitchen S,Iampietro R,Woolley AM,Preston FE.Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid:inter-assayvariability.Thromb Haemost1999;82:1289–1293.4Gori AM,Fedi S,Pepe G,Falciani M,Rogolino A,Prisco D,et al.Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration.Br JHaematol2002;117:693–698.5Green B,Greenwood M,Saltissi D,Westhuyzen J,Kluver L,Rowell J,et al.Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.Br J Clin Pharmacol2005;59:281–290. 6Al Dieri R,Alban S,Beguin S,Hemker HC.Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability,only partly correlated to body weight.J Thromb Haemost2006;4:83–89.7Mayr AJ,Dunser M,Jochberger S,Fries D,Klingler A,Joannidis M,et al.Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin.Thromb Res2002;105:201–204.8Kovacs MJ,Kearon C,Rodger M,Anderson DR,Turpie AG,Bates SM,et al.Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.Circulation2004;110:1658–1663.9Leizorovicz A,Bara L,Samama MM,Haugh MC.Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage.Haemostasis1993;23(Suppl1):89–98. 10Hammerstingl C,Omran H,Tripp C,Poetzsch B.How useful is determination of antifactor Xa activity to guide bridging therapy withenoxaparin?A pilot study.Thromb Haemost2009;101:325–332.11Bara L,Planes A,Samama MM.Occurrence of thrombosis and haemorrhage,relationship with anti-Xa,anti-IIa activities,and D-dimerplasma levels in patients receiving a low molecular weight heparin,enoxaparin or tinzaparin,to prevent deep vein thrombosis after hip surgery.Br J Haematol1999;104:230–240.12Barras MA,Duffull SB,Atherton JJ,Green B.Individualized compared with conventional dosing of enoxaparin.Clin Pharmacol Ther2008;83:882–888.13Chandler WL.The thromboelastography and the thromboelastograph technique.Semin Thromb Hemost1995;21(Suppl4):1–6.14Luddington RJ.Thrombelastography/thromboelastometry.Clin Lab Haematol2005;27:81–90.15Mallett SV,Cox DJ.Thrombelastography.Br J Anaesth1992;69:307–313. 16Hirsh J,Raschke R.Heparin and low-molecular-weight heparin:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest2004;126:188S–203S.17Mismetti P,Laporte-Simitsidis S,Navarro C,Sie P,d’Azemar P,Necciari J, et al.Aging and venous thromboembolism influence thepharmacodynamics of the antifactor Xa and antithrombin activities of a low molecular weight heparin(nadroparin).Thromb Haemost1998;79:1162–1165.18Reinhofer M,Brauer M,Franke U,Barz D,Marx G,Losche W.The value of rotation thromboelastometry to monitor disturbed perioperativehaemostasis and bleeding risk in patients with cardiopulmonary bypass.Blood Coagul Fibrinolysis2008;19:212–219. Thromboelastography for monitoring enoxaparin White et al.309。
心血管常用英文缩写
心血管常用缩写AA2 aortic second sound 主动脉区第二音AA amino acid 氨基酸AAA abdominal aortic aneurysm 腹主动脉瘤Ab antibody 抗体ABE acute bacterial endocarditis 急性细菌性心膜炎ABG arterial blood gases 动脉血气ABI ankle brachial inde* 踝肱指数ABP arterial blood pressure 动脉血压ABPM ambulatory blood pressure monitoring 动态血压监测AC alternating current 交流电AC aortic closure 动脉闭锁ACAT acyl CoA:cholesterol acyltransferase 胆固醇酰基转移酶ACE angiotensin converting enzyme 血管紧素转化酶ACEI angiotensin converting enzyme inhibitors 血管紧素转化酶抑制剂ACG angiocardiography 心血管造影术ACh acetylcholine 乙酰胆碱ACS acute coronary syndromes 急性冠状动脉综合症ACTH adrenocorticotropic hormone 促肾上腺皮质激素ADH antidiuretic hormone 抗利尿激素ADP adenosine diphosphate 二磷酸腺苷AECG ambulatory electrocardiography 动态心电图AEDs automatic e*ternal defibrillators 自动体外除颤器AF atrial fibrillation 房颤AFL atrial flutter 心房扑动AG atrial gallop 心房性奔马律AHA American Heart Association 美国心脏协会AHP apical hypertrophy 心尖部肥厚AI aortic inpetence 主动脉瓣关闭不全AI aortic insufficiency 主动脉瓣功能不全AI apical impulse 心尖搏动AICD automatic implantable cardioverter-defibrillator 埋藏式自动心脏复律除颤器AICDS automatic implanted cardioverter defibrillators 自动植入式心脏复律除颤器AIDS acquired immunodeficiency syndrome 爱滋病AIVR Accelerated idioventricular rhythm 加速性心室自主节律ALT alanine aminotransferase 丙氨酸氨基转移酶AMI acute myocardial imfarction 急性心肌堵塞AML anterior mitral valve leaflet 二尖瓣前叶ANA antinuclear antibody 抗核抗体ANCA antineutrophilic cytoplasmic antibodies 抗中性粒细胞胞浆抗体ANGII angiotensin II 血管紧素IIANOVA analysis of variance 方差分析ANP atrial natriuretic hormone 心房利钠激素ANP atrial natriuretic peptide 心房利钠肽ANS autonomic nervous system 自主神经系统Ao aorta 主动脉AO opening of the atrioventricular valves 房室瓣开AoP aortic pressure 主动脉压力AP accessory pathway 旁路AP action potential 动作电位AP angina pectoris 心绞痛AP arterial pressure 动脉压APB atrial premature beat 房性早搏APC atrial premature ple* 房性早搏APH apical hypertrophy 心尖部肥厚APA action potential amplitude 动作电位幅度APC activated protein C 活化的蛋白CAPD action potential duration 动作电位时间apoA apolipoprotein A 载脂蛋白AapoB apolipoprotein B 载脂蛋白BaPPT actived partial thromboplastin time 激活的局部凝血活酶时间APSAC anisolysated plasminogen streptokinase activated ple* 苯甲氧酰纤溶酶原链激酶活化复合物AR aortic regurgitation 主动脉瓣关闭不全AR alarm reaction 应激反响AR artificial respiration 人工呼吸ARDS adult respiratory distress syndrome 成人呼吸窘迫综合症Arg arginine 精氨酸ARP atrial refractory period 心房不应期ARVD arrhythmogenic right ventricular dysplasia 致心律失常性右心室发育不良AS aortic stenosis 主动脉瓣狭窄AS arteriosclerosis 动脉硬化ASCVD arteriosclerotic cardiovascular disease 动脉粥样硬化性心血管病ASD atrial septal defect 房间隔缺损ASH asymmetric septal hypertrophy 非对称性心室间隔肥厚ASHD arteriosclerotic heart disease 动脉硬化性心脏病ASO anti-streptolysin "O" 抗链球菌溶血素OASO arteriosclerosis obliterans 闭塞性动脉硬化AST aspartate aminotransferase 天门冬氨酸氨基转移酶AT angiotensin Ⅱ receptor 血管紧素Ⅱ受体AT atrial tachycardia 房性心动过速AT-Ⅲ:A antithrombin Ⅲ activity 抗凝血酶Ⅲ活性ATP adenosine triphosphate 三磷酸腺苷ATP antitachycardia pacing 抗心动过速起搏ATPase adenosinetriphosphatase 三磷酸腺苷酶AVA-V atrioventricular 房室性的AVN atrioventricular node 房室结AVNRT atrioventricular nodal reentrant tachycardia 房室结折返性心动过速AVO atrioventricular orifice 房室口AVP arginine vasopressin 精氨酸加压素AVR aortic valve replacement 主动脉瓣置换术AVRT atrioventricular reciprocating tachycardia 房室交互性心动过速BBBB blood-brain barrier 血脑屏障BBB bundle branch block 束支传导阻滞BBBB bilateral bundle branch block 双侧束支传导阻滞BBT basal body temperature 根底体温BDS biodegradable stents 生物可降解支架BFP biologic false-positive 生物学假阳性BLS basic life support 根底生命支持BMI body mass inde* 体质指数BMR basal metabolic rate 根底代率BNP brain natriuretic peptide 脑钠肽BUN blood urea nitrogen 尿素氮BP blood pressure 血压BPV blood pressure variability 血压波动性BRF renal blood flow 肾血流B.S. breath sounds 呼吸音B.S. blood sugar 血糖BSA body surface area 体外表积BUN blood urea nitrogen 血尿素氮BVAD biventricular assist device 两心室辅助装置CCA cardiac arrest 心脏停搏CA coronary artery 冠状动脉CA catecholamine 儿茶酚胺C.A. circumfle* coronary artery 左盘旋支冠状动脉CABG coronary artery bypass grafting 冠状动脉旁路移植术CABS coronary artery bypass surgery 冠状动脉分流术CAD coronary artery disease 冠状动脉疾病CAMP cyclic adenosine monophosphate 环磷酸腺苷CAVB plete atrioventricular block 完全房室传导阻滞CBC plete blood count 全血细胞计数CBF cerebral blood flow 脑血流量CC chief plaint 主诉CCPR cardiopulmonary-cerebral resuscitation 心肺脑复CCU coronary care unit 冠心病监护病房CCU critical care unit 危症监护病房CD curative dose 有效量治疗量CDC Centers for Disease Control and Prevention 疾病预防控制中心CEA carcinoembryonic antigen 癌胚抗原CEI cardiac effort inde* 心脏负荷指数CETP cholesteryl ester transfer protein 胆固醇酯转移蛋白CF cardiac failure 心力衰竭CFR coronary flow reserve 冠状动脉血流储藏cGMP cyclic guanosine monophosphate 环-磷酸鸟苷CHD coronary heart disease 冠心病CHF congestive heart failure 充血性心力衰竭CHO Chinese hamster ovary (cell) 中国仓鼠卵巢细胞CI cardiac inde* 心脏指数CIC circulating immune ple* 循环免疫复合物CIE counterimmunoelectrophoresis 对流免疫电泳CK creatine kinase 肌酸激酶CK-BB creatine kinase with brain subunits 肌酸激酶BB亚单位CK-MB creatine kinase-MB 肌酸激酶MB亚单位CK-MM creatine kinase with muscle subunits 肌酸激酶MM亚单位CM chylomicron 乳糜微粒CMLC cardiac myosin light chains 心脏肌凝蛋白轻链CMT circus movement tachycardia 环形运动性心动过速S central nervous system 中枢神经系统CO cardiac output 心输出量CoA coenzyme A 辅酶ACOPD chronic obstructive pulmonary disease 慢性阻塞性肺病CPB cardiopulmonary bypass 体外循环CPAP continuous positive airway pressure 持续气道正压呼吸CPC clinicopathological conference 临床病历讨论会CPK creatine phosphokinase 磷酸肌酸激酶CPK-MB MB fraction of creatine phosphokinase 磷酸肌酸激酶同功酶MBCPR cardiopulmonary resuscitation 心肺复CRH corticotropin-releasing hormone 促肾上腺皮质激素释放激素CRP C-reactive protein C反响蛋白CRT cardiac resynchronization therapy 心脏再同步治疗CS coronary sinus 冠状窦CSF colony-stimulating factor 集落刺激因子CSF cerebrospinal fluid 脑脊液CSM carotid sinus massage 颈动脉窦按摩CSNRT corrected SNRT 校正的窦房结恢复时间CT clotting time 凝血时间CT puted Tomography 计算机体层X线摄影CTA CT angiography CT血管造影cTnI cardiac troponin I 心肌肌钙蛋白IcTnT cardiac troponin T 心肌肌钙蛋白TCTO chronic total occlusion 慢性闭塞病变CV cardiovascular 心血管的CVA cerebrovascular accident 脑血管意外CVD cardiovascular disease 心血管疾病CVP central venous pressure 中心静脉压CVS cardiovascular system 心血管系统DDAD delayed afterdepolarization 延迟后去极化D.A.H disordered action of heart 心功能失调DBP diastolic blood pressure 舒压DC direct-current 直流电DCM dilated cardiomyopathy 扩性心脏病DHEA-S dehydroepiandrosterone sulfate 硫酸脱氢异雄酮DHF diastolic heart failure 舒性心力衰竭DIC disseminated intravascular coagulation 弥漫性血管凝血DL diffusion capacity 弥散量DM diabetes mellitus 糖尿病DM diastolic murmur 舒期杂音DNA deo*yribonucleic acid 脱氧核糖核酸DNR do not resuscitate 不复DOA dead on arrival 到达时已死亡DOC deo*ycorticosterone 脱氧皮质酮DSA digital subtraction angiography 数字减影血管造影术dsDNA double-stranded DNA 双链脱氧核糖核酸DTPA diethylenetriaminepentaacetic acid 二乙烯三胺五乙酸DVT deep venous thrombosis 深静脉血栓形成EEAD early afterdepolarization 早期后除极EAVNC enhanced A-V nodal conduction 房室结加速传导EBV Epstein-Barr virus EB病毒ECC e*ternal chest pression 胸外心脏按压ECG electrocardiogram 心电图ECMO e*tracorporeal membrane o*ygenation 体外循环膜氧合ECS electrocerebral silence 脑电静止ECS endocannabinoid system 分泌大麻系统ED emergency department 急诊室ED effective dose 有效剂量EDCFs endothelium-derived constricting factor 皮衍生的收缩因子EDHF endothelium-derived hyperpolarizing factor 皮衍生超极化因子EDRF endothelium-derived rela*ing factor 皮衍生的松弛因子EDV end-diastolic volume 舒末期容积EERP e*tended endocardial resection procedure 心膜伸展切除法EEV encircling endocardial ventriculotomy 心膜面心室环切术EF ejection fraction 射血分数EKG electrocardiogram 心电图ELISA enzyme-linked immunosorbent assay 酶联免疫吸附试验EMD electromechanical dissociation 电机械别离EMS emergency medical service 急救医疗效劳ERBF effective renal blood flow 有效肾血流量EPS electrophysiology study 电生理检查EPSP e*citatory postsynaptic potential 兴奋性突触后电位ER endoplasmic reticulum 质网ERBF effective renal blood flow 有效肾血流量ERP effective refractory period 有效适应期ERP endocardial resection procedure 心膜切除术ERT estrogen replacement therapy 雌激素替代疗法ERV e*piratory reserve volume 补呼气容积ES cells Embryonic stem cells 胚胎干细胞ESR erythrocyte sedimentation rate 血细胞沉降率ESRD end-stage renal disease 终末期肾脏疾病ESV end-systolic volume 收缩末期容积ET e*citability threshold 兴奋性阈值ET endothelin 皮素FFab fragmentantigen-binding 抗原结合片断FABP fatty acid binding protein 脂肪酸结合蛋白FBG fasting blood glucose 空腹血糖FDP fibrinogen degradation products 纤维蛋白原降解产物FEV1.0 forced e*piratory volume in one second 第1秒用力呼气容积FFA free fatty acid 游离脂肪酸FGF fibroblast growth factor 纤维母细胞生长因子FH familial hypercholesterolemia 家族性高胆固醇血症FHC familial hypertrophic cardiomyopathy 家族性肥厚型心肌病FIO2 fraction of inspired o*ygen 吸入气氧分数FML flail mitral leaflet 连枷样瓣叶FRC functional residual capacity 功能残气量FT3 free triiodothyronine 游离型T3FT4 free thyro*ine 游离型甲状腺素FUO fever of undetermined origin 不明原因发热FVC forced vital capacity 用力肺活量GGAD glutamic acid decarbo*ylase 谷氨酸脱羧酶GAP GTPase-activating protein GTP酶活化蛋白GBM glomerular basement membrane 肾小球基底膜G-CSF granulocyte colony-stimulating factor 粒细胞集落刺激因子GFR glomerular filtration rate 肾小球滤过率GHb glycosylated hemoglobin 糖化血红蛋白GI gastrointestinal 胃肠的GIK glucose_insulin_potassium 葡萄糖-胰岛素-钾〔极化液〕GITS the gastrointestinal therapeutic system 胃肠道治疗系统GMP guanosine monophosphate 一磷酸鸟苷GPBB glycogen phosphorylase isoenzyme 糖原磷酸化酶同工酶BB GPT glutamic-pyruvic transaminase 谷丙转氨酶GTP guanosine triphosphate 三磷酸鸟苷GTT glucose tolerance test 葡萄糖耐量试验HHAV hepatitis A virus 甲肝病毒Hb hemoglobin 血红蛋白HbA1c Hemoglobin A1c 糖化血红蛋白A1cHBcAg hepatitis B core antigen 乙肝核心抗原HBeAg hepatitis B e antigen 乙肝e抗原HBsAg hepatitis B surface antigen 乙肝e抗原HBE His bundle electrogram 希氏束电图HBV hepatitis B virus 乙肝病毒HbO2 o*yhemoglobin 氧合血红蛋白HCM hypertrophic cardiomyopathy 肥厚型心肌病HCT hematocrit 血细胞比容,红细胞压积HDL-C high-density lipoprotein cholesterol 高密度脂蛋白胆固醇HERG Human Ether-a-go-go-Related Gene 人类eag相关基因HF heart failure 心力衰竭hFABP heart fatty acid binding protein 心脏脂肪酸结合蛋白HIT heparin-induced thrombocytopenia 肝素导致的血小板减少症HIV human immunodeficiency virus 人类免疫缺陷病毒HLHS hypoplastic left heart syndrome 左心发育不良综合征HMG-COA 3-hydro*y-3-methylglutaryl coenzyme A 3羟甲基戊二酰辅酶AHMWK high molecular weight kininogen 高分子量激肽原HOCM hypertrophic obstructive cardiomyopathy 肥厚梗阻性心肌病HOP high o*ygen pressure 高压氧HP haptoglobin 结合珠蛋白,触珠蛋白HPI history of the present illness 现病史HPS His-Purkinje system 希氏束-浦肯野系统HR heart rate 心率HRV heart rate variability 心率变异性HuIFN human interferon 人体干扰素IIAB intraaortic balloon 主动脉气囊IABP intraaortic balloon pump 主动脉气囊泵IC inspiratory capacity 深吸气量ICD implantable cardioverter-defibrillator 埋藏式心脏复律-除颤器ICU intensive care unit 重症监护病房IDD insulin-dependent diabetes 胰岛素依赖性糖尿病IDL intermediate-density lipoprotein 中间密度脂蛋白IE infective endocarditis 感染性心膜IFG impaired fasting glucose 空腹血糖调节受损IFN interferon 干扰素IGF-1 insulin-like growth factor-1 胰岛素样生长因子-1IGT impaired glucose tolerance 葡萄糖耐量降低IHD ischemic heart disease 缺血性心脏病IHR intrinsic heart rate 固有心率IHSS idiopathic hypertrophy subaortic stenosis 特发性肥厚型主动脉瓣下狭窄IHUT isoproterenol-head-up tilt testing 异丙肾上腺素-倾斜试验IMA internal mammary artery 乳动脉INR international normalized ratio 国际标准化比值IPG impedance plethysmography 阻抗容积描记法IPPB intermittent positive pressure breathing 间歇性正压呼吸IR insulin resistance 胰岛素抵抗IRMS insulin resistance metabolic syndrome 胰岛素抵抗代综合征IRS insulin resistance syndrome 胰岛素抵抗综合征IRV inspiratory reserve volume 补吸气容积ISA intrinsic sympathomimetic activity 源性拟交感活性IU international unit 国际单位IV intravenously 静脉注射IVC inferior vena cava 下腔静脉IVP intravenous pyelography 静脉肾盂造影IVRT isovolumic rela*ation time 等容舒时间IVS interventricular septum 室间隔IVST interventricular septal thickness 室间隔厚度IVUS intravascular ultrasound 血管超声JJ joule 焦耳KKD Keshan disease 克山病LLA left arm 左臂LA left atrium 左心房LAD left anterior descending (coronary artery) 冠状动脉左前降支LAD left a*is deviation 电轴左偏]LADA latent autoimmune diabetes in adult 成人隐匿自身免疫糖尿病LAE left atrial enlargement 左心房扩大LAFB left anterior fascicular block 左前分支阻滞LAH left anterior hemiblock 左前分支阻滞LAO left anterior oblique 左前斜位LAP left atrial pressure 左心房压力LAPB left anterior parietal block 左前分支末梢阻滞LATS long-acting thyroid stimulator 长效甲状腺刺激素LBBB left bundle branch block 左束支传导阻滞LCA left coronary artery 左冠状动脉LCAT lecithin :cholesterol acyltransferase 卵磷脂胆固醇酰基转移酶LC* left circumfle* artery 左冠状动脉盘旋支LDH lactate dehydrogenase 乳酸脱氢酶LDL-C low-density lipoprotein cholesterol 低密度脂蛋白胆固醇LF left leg 左腿LP(α) α-lipoprotein α脂蛋白LPFB left posterior fascicular block 左后分支阻滞LPH left posterior hemiblock 左后半阻滞LPL lipoprotein lipase 脂蛋白酯酶LQ-T1 long Q-T locus 1 长Q-T位点1LQTS long QT syndrome 长QT综合症LRL lower rate limit 下限频率LV left ventricle 左心室LVAD left ventricular assist device 左室辅助装置LVEDP left ventricular end-diastolic pressure 左室舒末压LVEDV left ventricular end-diastolic volume 左室舒末容积LVET left ventricular ejection time 左心室射血时间LVH left ventricular hypertrophy 左室肥厚LVMI left ventricular mass inde* 左室重量指数MMAF macrophage activating factor 巨噬细胞活化因子MAG3 mercaptoacetyltriglycine 巯基乙酰三甘氨酸MAO monoamine o*idase 单胺氧化酶MAOI monoamine o*idase inhibitor 单胺氧化酶抑制剂MAP mean arterial pressure 平均动脉压MAPK mitogen-actived protein kinase 有丝分裂激活的蛋白激酶MAT multifocal atrial tachycardia 多源性房性心动过速MBC minimum bactericidal concentration 最小杀菌浓度MB-CK MB creatine kinase 肌酸磷酸激酶MB亚单位MCE myocardial contrast echocardiography 心肌造影超声心动图MCF macrophage chemotactic factor 巨噬细胞趋化因子MCH mean corpuscular hemoglobin 红细胞平均血红蛋白量MCHC mean corpuscular hemoglobin concentration 红细胞平均血红蛋白浓度MCT mean circulation time 平均循环时间MCV mean corpuscular volume 平均红细胞容积MDF myocardial depressant factor 心肌抑制因子MDP ma*imum diastolic potential 最大舒电位MEN multiple endocrine neoplasia 多发性分泌肿瘤METS multiple of basal metabolic o*ygen consumption 根底代氧消耗倍数MHC myosin heavy chain 肌球蛋白重链MI myocardial imfarction 心肌堵塞MIC minimum inhibitory concentration 最小抑菌浓度MLC myosin light chain 肌凝蛋白轻链MMD minor myocardial damage 微小心肌损伤MODS multiple organ dysfunction syndrome 多脏器功能障碍综合征MPD ma*imum permissible dose 最大允许剂量MPS mononuclear phagocyte system 单核巨噬细胞系统MPS mucopolysaccharidosis 粘多糖〔贮积〕病MR mitral regurgitation 二尖瓣关闭不全MRA magnetic resonance angiography 核磁共振血管造影MRI magnetic resonance imaging 核磁共振显像mRNA messenger RNA 信使核糖核酸MS metabolic syndrome 代综合征MS mitral stenosis 二尖瓣狭窄MSCT multi-slice puted tomography 多层螺旋CTMSCTCA MSCT coronary angiography 多层螺旋CT冠状动脉造影MSL midsternal line 胸骨中线MV mitral valve 二尖瓣MVO2 myocardial o*ygen requirements 心肌需氧量MVP mitral valve prolapse 二尖瓣脱垂MVV ma*imal voluntary ventilation 最大自主通气量NNBTE nonbacterial thrombotic endocarditis 非细菌性血栓性心膜炎NED no evidence of disease 无疾病证据NEFA nonesterified fatty acids 非酯型脂肪酸游离脂肪酸NEP neutral endopeptidase 中性肽酶NIDD non-insulin-dependent diabetes 非胰岛素依赖性糖尿病NMR nuclear magnetic resonance 核磁共振NO nitric o*ide 一氧化氮NPN nonprotein nitrogenNQWMI non-Q-wave myocardial infarction 非Q波心肌堵塞NSAIA nonsteroidal anti-inflammatory analgesic 非类固醇消炎止痛药NSAIDs nonsteriodal anti-inflammatory drugs 非甾族抗炎药物NSR normal sinus rhythm 正常窦律NTP normal temperature and pressure 正常体温与血压NVE native valve endocarditis 自身瓣膜心膜炎NYHA New York Heart Association 纽约心脏协会OOMB obtuse marginal branch 钝缘支OR operating room 手术室OS opening snap 开放拍击音OSAS obstructive sleep apnea syndrome 阻塞性睡眠呼吸暂停综合征OTC over the counter 非处方药物OTD organ tolerance dose 器官耐受剂量(*线)PP2 pulmonic second sound 肺动脉第二心音PA posteroanterior 后前位的PA pulmonary artery 肺动脉PAC premature atrial ple* 期前心房复合波PAF platelet-activating factor 血小板激活因子PAI-1 plasminogen activator inhibitor-1 纤维蛋白酶原激活物抑制剂-1PAP plasmin-antiplasmin ple* 纤溶酶抗纤溶酶复合物PAT paro*ysmal atrial tachycardia 阵发性房性心动过速PAWP pulmonary artery wedge pressure 肺动脉楔压力PBAV percutaneous balloon aortic valvuloplasty 经皮球囊主动脉瓣成形术PBMV percutaneous balloon mitral valvuloplasty 经皮球囊二尖瓣成形术PBPV percutaneous balloon pulmonary valvuloplasty 经皮球囊肺动脉瓣成形术PC:A protein C activity 蛋白C活性PCG phonocardiogram 心音图PCI percutaneous coronary intervention 经皮冠状动脉介入干预Pco2 carbon dio*ide partial pressure 二氧化碳分压力Pco2 carbon dio*ide partial tension 二氧化碳分力PCR polymerase chain reaction 聚合酶链反响PCV packed cell volume 血细胞压积PCWP pulmonary capillary wedge pressure 肺毛细血管楔压PDA patent ductus arteriosus 动脉导管未闭PDA posterior descending coronary artery 冠脉后降支PDE phosphodiesterase 磷酸二酯酶PDIs Phosphodiesterase inhibitors 磷酸二酯酶抑制剂PDGF platelet derived growth factor 血小板源生长因子PEA pulseless electrical activity 无脉性电活动PEEP positive ende*piratory pressure 呼气末正压呼吸PES programmed electrical stimulation 程控电刺激PET positron emission-puted tomography 正电子发射型计算机断层显像PF4 platelet factor 4 血小板第4因子PG prostaglandin 前列腺素PGI2 prostacyclin 前列环素PICVI Percutaneous in situ coronary venous arterialization 经皮原位冠状静脉动脉化PJRT permanent junctional repciprocating tachycardia 持久性交界性交互心动过速PJT paro*ysmal junctional tachycardia 阵发性交界性心动过速PKC protein kinase C 蛋白激酶CPLAATO Percutaneous Left Atrial Appendage Transcatheter Occluder 经皮导管左心耳闭塞器PLS prolonged life support 延续生命支持PMI point of ma*imal impulse 最强心尖搏动点PMVL posterior mitral valve leaflet 二尖瓣后叶PMT pacemaker mediated tachycardia 起搏器介入性心动过速PO2 o*ygen partial pressure 氧分压力PO2 o*ygen partial tension 氧分力POCT point of care test 床旁检查PPAR pero*isome proliferator-activated receptor 过氧化物酶体增生物活化受体PPD purified protein derivative (tuberculin) 精制蛋白衍化物〔结核菌素〕PR peripheral resistance 外周阻力PR pulmonic regurgitation 肺动脉瓣关闭不全PRA plasma renin activity 血浆肾素活性PRG phleborheography 静脉血流描记法PS protein S 蛋白SPS pulmonic stenosis 肺动脉瓣狭窄PS pulmonary stenosis 肺动脉瓣狭窄PSM presystolic murmur 收缩前杂音PSVT paro*ysmal supraventricular tachycardia 阵发性室上性心动过速PT prothrombin time 凝血酶原时间PT pulmonary trunk 肺动脉干PTA plasma thromboplastin 血浆凝血致活酶前质PTC plasma thromboplastin ponent 血浆凝血致活酶成分PTCA percutaneous transluminal coronary angioplasty 经皮冠状动脉血管成形术Ptf P- wave terminal force 心房终末电压PTT partial thromboplastin time 局部凝血活酶时间PUO pyre*ia of unknown origin 原因不明的发热,无名热PVCs premature ventricular contractions 室性早搏PVE prosthetic valve endocarditis 人工瓣膜性心膜炎PVR pulmonary vascular resistance 肺血管阻力PVT polymorphic ventricular tachycardia 多形性室性心动过速PWT posterior wall thickness 后壁厚度QQMI Q_wave myocardial infarction Q波型心肌堵塞QTd Q-T dispersion Q-T离散度QTc corrected QT interval 校正的QT间期RRA right arm 右臂RA right atrium 右心房RAD right a*is deviation 电轴右偏RAAS renin-angiotensin-aldosterone system 肾素-血管紧素-醛固酮系统RAE right atrial enlargement 右心房扩大RAO right anterior oblique 右前斜位RAS renin-angiotensin system 肾素-血管紧素系统RBBB right bundle branch block 右束支传导阻滞RBC red blood cell 红细胞RBC red blood (cell) count 红细胞计数RCA right coronary artery 右冠状动脉RCM restrictive cardiomyopathy 限制性心肌病RCTs randomized controlled trials 随机对照研究RES reticuloendothelial system 网状皮系统RF rheumatoid factor 类风湿因子RFCA radiofrequency catheter ablation 射频消融术RFLP restriction fragment length polymorphism 限制性片段长度多态性PHC Right-sided heart catheterization 右心导管检查RIST radioimmunosorbent test 放射免疫吸附试验RKY roentgenkymography *线记波照相术RNA ribonucleic acid 核糖核酸RNP ribonucleoprotein 核糖核酸蛋白ROM passive range of motion 被动活动ROSC return of spontaneous circulation 自主循环恢复RPF renal plasma flow 肾血浆流量RPS renal pressor substance 肾加压物质RQ respiratory quotient 呼吸商rT3 reverse triiodothyronine 反三碘甲状腺原氨酸r-TPA rebinant tissue plasminogen activator 重组的组织型纤溶酶原激活物RV residual capacity 残气量RV right ventricle 右心室RVAD right ventricular assist device 右心室辅助装置RVH right ventricular hypertrophy 右心室肥大RVI right ventricle infarction 右心室堵塞RVOT right ventricular outflow Tract 右室流出道SS1 first heart sound 第一心音S2 second heart sound 第二心音S3 third heart sound 第三心音S4 fourth heart sound 第四心音SA sinoatrial 窦房的SACT sinoatrial conduction time 窦房传导时间SAB sinoatrial block 窦房阻滞SAECG signal averaged electrocardiogram 信号叠加心电图SAH systemic arterial hypertension 体循环动脉高压SAH subarachnoid hemorrhage 蛛网膜下腔出血SAM systolic anterior motion 〔二尖瓣前叶〕在收缩期前移SB sinus bradycardia 窦性心动过缓SBE subacute bacterial endocarditis 亚急性细菌性心膜炎SBP systolic blood pressure 收缩压SBT serum bactericidal titer 血清杀菌剂滴度SC closure of the semilunar valves 半月瓣关闭SC subcutaneous 皮下SCD sudden cardiac death 心脏性猝死scu-PA single chain urokinase-type plasminogen activator 单链尿激酶型纤溶酶原激活物SD standard deviation 标准差SE stress echocardiography 负荷超声心动图SE standard error 标准误差SEC spontaneous echo contrast 自发性声学显影SFMC soluble fibrin monomer ple* 可溶性纤维蛋白单体复合物SGOT glutamic o*aloacetic acid transferase 血清谷草转氨酶SH sulfhydryl 巯基SHR spontaneously hypertensive rat 自发性高血压大鼠SHRSP strok-prone SHR 具有中风倾向的自发性高血压大鼠SIRS systemic inflammatory response syndrome 全身炎症反响综合征SK streptokinase 链激酶SL sublingual 舌下SLE systemic lupus erythematosus 系统性红斑狼疮SM systolic murmur 收缩期杂音SMBG self-monitoring blood glucose 自我监测血糖SMCS smooth muscle cells 平滑肌细胞SMI silent myocardial ischemia 无病症性心肌缺血SNRT sinus node recovery time 窦房结恢复时间SNS sympathetic nervous system 交感神经系统SOB shortness of breath 呼吸短促SPECT single photon emission puted tomography 单光子发射型计算机断层显像SQTS short Q-T syndrome 短Q-T 间期综合征SR sarcoplasmic reticulum 肌浆质网ssDNA single-stranded DNA 单链DNASSS sick sinus syndrome 病态窦房结综合症ST sinus tachycardia 窦性心动过速STI systolic time intervals 心室收缩时间间期SUDS sudden une*plained death syndrome 不明原因猝死综合症SUNDS sudden une*plained nocturnal death syndrome 不明原因的夜间猝死综合症SV stroke volume 每搏心输出量SVC superior vena cava 上腔静脉SVI stroke volume inde* 每搏量指数SVT supraventricular tachycardia 室上性心动过速SWI stroke work inde* 每搏作功指数TTa atrial repolarization 心房复极TABD triple acid-base disorders 三重性酸碱失衡TAT thrombin -antithrombin ple* 凝血酶-抗凝血酶复合物TC total cholesterol 总胆固醇Tc technetium 锝TDI tissue doppler imaging 组织多普勒成像TDP torsades de pointes 尖端扭转性室性心动过速TEE transesophageal echocardiography 经食道超声心动图TET treadmill e*ercise test 踏车运动试验TFPI tissue factor pathway inhibitor 组织因子途径抑制物TGA transposition of the great arteries 大动脉转位TGB thyro*ine-binding globulin 甲状腺素结合球蛋白TGF-β transforming growth factor-beta 转化生长因子βTHAM tromethamine 三羟甲基氨基甲烷TIA transient ischemic attack 短暂性脑缺血发作TIMI thrombolysis in myocardial infarction 心肌堵塞溶栓TLC total lung capacity 肺总量TM thrombomodulin 血栓调节蛋白TMLR transmyocardial laser revascularization 心肌再血管化TMST treadmill e*ercise test 踏车运动试验TNF tumor necrosis factor 肿瘤坏死因子T-PA tissue-type plasminogen activator 组织型纤溶酶原激活物TPP thrombus precussor protein 血栓前体蛋白TR tricuspid regurgitation 三尖瓣返流TRH thyrotropin-releasing hormone 促甲状腺素释放激素TS tricuspid stenosis 三尖瓣狭窄TSH thyroid-stimulating hormone 促甲状腺素TT thrombin time 凝血酶时间TT thrombolytic therapy 溶栓治疗TTE transthoracic echocardiography 经胸超声心动图TV tricuspid valve 三尖瓣T*A2 thrombo*ane A2 血栓烷A2T*B2 thrombo*ane B2 血栓烷B2UUA unstable angina 不稳定性心绞痛UCG ultrasound cardiogram 超声心动图UCM unclassified cardiomyopathies 不定型的心肌病UK urokinase 尿激酶u-PA urokinase type plasminogen activator 尿激酶型纤溶酶原激活物URL upper rate limit 上限频率URTI upper respiratory tract infection 上呼吸道感染US ultrasound 超声VV4R right precordial lead in V4 position 右胸导联V4的位置VAD ventricular assist device 心室辅助装置VC vital capacity 肺活量VCAM vascular cell adhesion molecule 血管细胞粘附分子VCG vectorcardiogram 心电向量图Vco2 carbon dio*ide 二氧化碳产量VDH valvular disease of the heart 心瓣膜病VE minute ventilation 每分钟通气量VEDP ventricular end-diastolic pressure 心室舒末压力VEGF vascular endothelial growth factor 血管皮细胞生长因子VF ventricular fibrillation 室颤VFT ventricular fibrillation threshold 室颤阈值VLDL very-low-density lipoprotein 极低密度脂蛋白VLP ventricular late potential 心室晚电位VMA vanillylmandelic acid 香草扁桃酸Vo2 peak o*ygen consumption 峰值氧耗Vo2 respiratory o*ygen uptake 呼吸摄氧量VMA vanillylmandelic acid 3-甲氧基-4羟基苦杏仁酸VPBs ventricular premature beats 室性早搏VPC ventricular premature ple* 心室早搏复合波VPD ventricular premature depolarization 心室过早去极化VRP ventricular refractory period 心室不应期VSD ventricular septal defect 室间隔缺损VT ventricular tachycardia 室性心动过速VTE venous thromboembolism 静脉血栓栓塞VW vessel wall 血管壁vWF von willebrand factor 血管性血友病因子WWBC white blood cell 白细胞WBC white blood (cell) count 白细胞计数WHO world health organization 世界卫生组织α-MHC alpha-myosin heavy chain α-肌凝蛋白重链β-TG β-th romboglobulin β-血小板球蛋白23-DPG 23-diphosphoglycerate 23-二磷酸甘油酸5-HT 5-hydro*ytryptamine 5-羟色胺123I MIBG iodine-123 metaiodobenzylguanidine I123标记的间碘苄胍17-KS 17-ketosteroids 17-酮皮质类固醇17-OHCS 17-hydro*ycorticosteroid 17-羟皮质类固醇18-OHD 18-hydro*ycorticosterone 18-羟皮质酮24hUFC 24h urine free cortisol 24小时尿液游离皮质醇。
多系统器官衰竭(英文)
respiratory, cardiovascular, renal, hepatic, gastrointestinal, hematological, endocrine, and central nervous system.
Multi System Organ Failure (MSOF). They concluded that MOF syndrome was the result of a combination of preexisting disease and hemorrhagic shock.
1980’s - began to realize concept of sepsis. MOF was
mechanism
The mechanisms of MODS are enormously complex and poorly understood. Systemic inflammatory response syndrome (SIRS) is the main reason of MODS.
mechanism
To every action there is always opposed an equal reaction:
or, the mutual action of two bodies upon each other are always equal, and directed to contrary parts. -Sir Isaac Newton, 1687
secondary: tardy, after an initial organ dysfunction
血浆灭活:Human plasma (pooled and treated for virus)
11.0It is not intended that the determination of total protein and human coagulation factor VIII shown below be carried out on each unit of plasma.They are rather given as guidelines for good manufacturing practice,the test for human coagulation factor VIII being relevant for plasma intended for use in the preparation of concentrates of labile proteins.The total proteincontentof a unitof plasma depends on theserum protein content of the donor and the degree of dilution inherent in the donation procedure.When plasma is obtained from a suitable donorandusing the intendedproportionofanticoagulant solution,a total protein content complying with the limit of 50 g/L is obtained.If a volume of blood or plasma smaller than intended is collected into the anticoagulantsolution,the resulting plasma is not necessarily unsuitable forpooling for fractionation.The aim of good manufacturing practice must be to achieve the prescribed limit for all normal donations.Preservation of human coagulation factor VIII in the donation depends on the collection procedure and the subsequent handling of the bloodandplasma.Withgoodpractice,0.7 IU/mL can usually be achieved,but units of plasma with alower activity may still be suitable for use in the production of coagulation factor concentrates.The aim of allstepstakenduring production of plasma is to obtain plasma of the intended quality and to conserve labile proteins as much as possible.Total protein .Carry out the test using a pool of not fewer than 10 units.Dilute anappropriate volume of the preparationwith a 9 g/L solution of sodium chloride R to obtain a solution containing about 15 mg of protein in 2 mL.To 2.0 mL of this solution in a round-bottomedcentrifugetube,add 2 mLof a 75 g/L solution of sodium molybdate R and 2 mL of a mixture of 1 volume of nitrogen-free sulfuric acid R and 30 volumes of water R .Shake,centrifuge for 5 min,decantthe supernatant and allow the inverted tube to drain on filter paper.Determine the nitrogen in the residue by the method of sulfuric acid digestion (2.5.9)and calculate the protein content by multiplying the quantity of nitrogen by 6.25.The total protein content is not less than 50 g/L.Human coagulation factor VIII (2.7.4).Carry out the test using a pool ofnot fewer than10 units.Thawthe samples tobe examined,if necessary,at 37 °C.Carry out the assay using a reference plasma calibrated against the International Standard for human coagulation factor VIII in plasma.The activity is not less than 0.7 IU/mL.STORAGE AND TRANSPORT Frozen plasma is stored and transported in conditions designed to maintain the temperature at or below − 20 °C;for accidental reasons,the storage temperature may riseabove − 20 °C on one or more occasions during storage and transport but the plasma is nevertheless considered suitable for fractionation if all the following conditions are fulfilled:–the total period of time during which the temperature exceeds − 20 °C does not exceed 72 h;–the temperature does not exceed − 15 °C on more than 1 occasion;–the temperature at no time exceeds − 5 °C.POOLED PLASMA During the manufacture of plasma products,the first homogeneous pool of plasma (for example,after removal of cryoprecipitate)is tested for HBsAgand forHIV antibodies using test methods of suitable sensitivity and specificity;the pool must give negative results in these tests.The plasma pool is also tested for hepatitis C virus RNA using a validated nucleicacid amplificationtechnique (2.6.21).Apositive control with 100 IU/mL of hepatitis C virus RNA and,to test for inhibitors,an internal control prepared by addition of a suitable markerto asampleof the plasma pool areincluded in the test.The test is invalid if the positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors.The plasma pool complies with the test if it is found non-reactive for hepatitis C virus RNA.Hepatitis C virus RNA for NAT testing BRP is suitable for use as a positive control.CHARACTERS Before freezing:clear or slightly turbid liquid without visible signsof haemolysis;it may vary in colour from light yellow to BELLINGThe label enables each individual unit to be traced to a specific donor.01/2020:1646corrected 11.0HUMAN PLASMA (POOLED AND TREATED FOR VIRUS INACTIVATION)Plasma humanum coagmentatum conditumque ad exstinguendum virum DEFINITIONSterile,frozen orfreeze-dried,non-pyrogenicpreparationobtained from human plasma derived from donors belonging to the same ABO blood group.The preparation is thawed orreconstituted before use to give a solution for infusion.The human plasma used complies with the monographHuman plasma for fractionation (0853).PRODUCTION The units of plasma to be used are cooled to − 30 °C or lower within 6 h of separation of cells and always within 24 h of collection.The pool is prepared by mixing units of plasma belonging to the same ABO blood group.PLASMA POOL TESTS The poolof plasma is tested for hepatitis B surface antigen(HBsAg)and for HIV antibodies using test methods of suitable sensitivity and specificity;the pool must give negative results in these tests.Hepatitis Avirus RNA.The plasmapool is tested using avalidated nucleic acid amplification technique (2.6.21).Apositive control with 1.0 × 102 IU of hepatitis A virus RNA per millilitre and,to testfor inhibitors,aninternal controlprepared by addition of a suitable marker to a sample of theplasma pool are included in the test.The test is invalid if the positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors.The pool complies with the test if it is found non-reactive for hepatitis A virus RNA.Hepatitis A virus RNA for NAT testing BRP is suitable for useas a positive control.Hepatitis C virus RNA .The plasma pool is tested using a validated nucleic acid amplification technique (2.6.21).A positive control with 1.0 × 102IU of hepatitis Cvirus RNAper millilitre and,to test for inhibitors,an internal control prepared by addition of a suitable marker to a sample of theplasma pool are included in the test.The test is invalidifthe positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors.Thepool complies with the test if it is found non-reactive for hepatitis C virus RNA.Hepatitis C virus RNA for NAT testing BRP is suitable for useas a positive control.General Notices (1)apply to all monographs and other texts 300511.0Hepatitis E virus RNA.The plasma pool is tested using a validated nucleic acid amplification technique(2.6.21).A positive control with3.2 × 102 IU of hepatitis E virus RNA per millilitre and,to test for inhibitors,an internal control prepared by addition of a suitable marker to a sample of the plasma pool are included in the test.The test is invalid ifthe positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors. The pool complies with the test if it is found non-reactive for hepatitis E virus RNA.Hepatitis E virus RNA for NAT testing BRP is suitable for use as a positive control.B19 virus DNA.The plasma pool contains not more than 10.0 IU/μL.To limit the potential burden of B19 virus in plasma pools, the plasma pool is also tested for B19 virus using a validated nucleic acid amplification technique(2.6.21).A positive control with10.0 IU of B19 virus DNA per microlitre and,to test for inhibitors,an internal control prepared by additionof a suitable marker to a sample of the plasma pool are included in the test.The test is invalid if the positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors.B19 virus DNA for NAT testing BRP is suitable for use as a positive control.METHOD OF PREPARATIONThe method of preparation is designed to minimise activation of any coagulation factor(to minimise potential thrombogenicity)and includes a step or steps that have been shown to inactivate known agents of infection;if substances are used for the inactivation of viruses during production, the subsequent purification procedure must be validated to demonstrate that the concentration of these substances is reduced to a suitable level and that any residues are such as not to compromise the safety of the preparation for patients. Inactivation process.The solvent-detergent process,which is one of the methods used to inactivate enveloped viruses, uses treatment with a combination of tributyl phosphate and octoxinol 10;these reagents are subsequently removed by oil extraction or by solid phase extraction so that the amount in thefinal product is less than2 μg/mL for tributyl phosphate and less than5 μg/mL for octoxinol 10.No antimicrobial preservative is added.The solution is passed through a bacteria-retentivefilter, distributed aseptically into thefinal containers and immediately frozen;it may subsequently be freeze-dried. Plastic containers comply with the requirements for sterile plastic containers for human blood and blood components (3.3.4).Glass containers comply with the requirements for glass containers for pharmaceutical use(3.2.1). CHARACTERSAppearance:–frozen preparation:clear or slightly opalescent liquid,free from solid and gelatinous particles after thawing;–freeze-dried preparation:almost white or slightly yellow powder or friable mass.Thaw or reconstitute the preparation to be examined as stated on the label immediately before carrying out the identification, tests and assay.IDENTIFICATIONA.Examine by electrophoresis(2.2.31)comparing withnormal human plasma.The electropherograms show the same bands.B.It complies with the test for anti-A and anti-Bhaemagglutinins(see Tests).TESTSpH(2.2.3):6.5to7.6.Osmolality(2.2.35):minimum240 mosmol/kg.Total protein:minimum45 g/L.Dilute if necessary with a9 g/L solution of sodium chloride R to obtain a protein concentration of about7.5 mg/mL.Place 2.0 mL of this solution in a round-bottomed centrifuge tube and add2 mL of a75 g/L solution of sodium molybdate R and 2 mL of a mixture of1 volume of nitrogen-free sulfuric acid R and30 volumes of water R.Shake,centrifuge for5 min,decant the supernatant and allow the inverted tube to drain onfilter paper.Determine the nitrogen in the residue by the method of sulfuric acid digestion(2.5.9)and calculate the quantity of protein by multiplying the result by6.25.Activated coagulation factors(2.6.22).It complies withthe test for activated coagulation factors.Carry out the test with0.1 mL of the preparation to be examined instead of10-fold and100-fold dilutions.The coagulation time for the preparation to be examined is not less than150 s.Anti-A and anti-B haemagglutinins(2.6.20,Method A).The presence of haemagglutinins(anti-A or anti-B)corresponds to the blood group stated on the label.Hepatitis A virus antibodies:minimum0.3 IU/mL, determined by a suitable immunochemical method(2.7.1). Human hepatitis A immunoglobulin BRP is suitable for use as a reference preparation.Irregular erythrocyte antibodies.The preparation to be examined does not show the presence of irregular erythrocyte antibodies when examined without dilution by an indirect antiglobulin test.Citrate.Liquid chromatography(2.2.29).Test solution.Dilute the preparation to be examined with an equal volume of a9 g/L solution of sodium chloride R.Filter through a membranefilter(nominal pore size0.45 μm). Reference solution.Dissolve0.300 g of sodium citrate R in water R and dilute to100.0 mL with the same solvent. Column:–size:l = 0.3 m,Ø = 7.8 mm;–stationary phase:cation-exchange resin R(9 μm).Mobile phase:0.51 g/L solution of sulfuric acid R.Flow rate:0.5 mL/min.Detection:spectrophotometer at215 nm.Equilibration:15 min.Injection:10 μL.Retention time:citrate = about10 min.Limit:–citrate:maximum25 mmol/L.Calcium:maximum5.0 mmol/L.Atomic absorption spectrometry(2.2.23,Method I). Source:calcium hollow-cathode lamp using a transmission band preferably of0.5 nm.Wavelength:622 nm.Atomisation device:air-acetylene or acetylene-propaneflame. Potassium:maximum5.0 mmol/L.Atomic emission spectrometry(2.2.22,Method I). Wavelength:766.5 nm.Sodium:maximum200 mmol/L.Atomic emission spectrometry(2.2.22,Method I). Wavelength:589 nm.Water.Determined by a suitable method,such as thesemi-micro determination of water(2.5.12),loss on drying (2.2.32)or near-infrared spectroscopy(2.2.40),the water content is within the limits approved by the competent authority(freeze-dried product).3006See the information section on general monographs(cover pages)11.0Sterility (2.6.1).It complies with the test.Pyrogens (2.6.8)or Bacterial endotoxins (2.6.14).It complieswith the test for pyrogens or,preferably and where justified and authorised,with a validated in vitro test such as the bacterial endotoxin test.For the pyrogen test,inject 3 mL per kilogram of the rabbit’s mass.Where the bacterial endotoxin test is used,the preparation to be examined contains less than 0.1 IU of endotoxin per millilitre.ASSAY Assay of humancoagulationfactor VIII(2.7.4).Use a reference plasma calibrated against the International Standard for blood coagulation factor VIII in plasma.The estimated potency is not less than 0.5 IU/mL.The confidence limits (P = 0.95)are not less than 80 per cent and not more than 120 per cent of the estimated potency.Assay of human coagulation factor V .Carry out the assay of human coagulationfactor V described below using a reference plasma calibrated against the International Standard for blood coagulation factor V in ing imidazole buffer solution pH 7.3 R ,prepare at least 3 twofold dilutions of the preparation to be examined,preferably in duplicate,from 1in 10to 1in 40.Test each dilution as follows:mix 1 volume of plasma substrate deficient in factor V R,1 volume of the dilutionto be examined,1 volume of thromboplastin R and 1 volume of a 3.5 g/L solution of calcium chloride R ;measure the coagulation times,i.e.the interval betweenthemomentat which thecalcium chloride solution is added and the 1st indication of the formation of fibrin,which may be observed visually or by means of a suitable apparatus.In the same manner,determine the coagulation time of 4 twofold dilutions (1in 10to 1in 80)of human normalplasma in imidazole buffer solution pH 7.3 R .Check thevalidity of the assay and calculate the potency of the test preparation by the usual statistical methods (for example, 5.3).The estimated potency is not less than 0.5 IU/mL.The confidence limits (P = 0.95)are not less than 80 per cent and not more than 120 per cent of the estimated potency.Assay of human coagulation factor XI (2.7.22).Use a reference plasma calibrated against the International Standard for blood coagulation factor XI in plasma.The estimated potency is notlessthan0.5 IU/mL.The confidence limits (P = 0.95)are not less than 80 per cent and not more than 125 per cent of the estimated potency.Coagulation factors V,VIII,XI and XIII plasma BRP is suitable for use as a reference preparation in the above assays.Assay of human protein C (2.7.30).Use a reference plasma calibrated against the International Standard for human protein C in plasma.The estimated potency is not less than 0.7 IU/mL.The confidence limits (P = 0.95)are not less than 80 per cent and not more than 120 per cent of the estimated potency.Assay of human protein S (2.7.31).Use a reference plasma calibrated against the International Standard for human protein S in plasma.The estimated potency is within the limits approved for the particular product.The confidence limits (P = 0.95)are not less than 80 per cent and not more than 120 per cent of the estimated potency.Assay of human plasmin inhibitor (2.7.25)(α2-antiplasmin).Use a reference plasma calibrated against human normal plasma.1 unit of human plasmin inhibitor is equal to the activity of 1 mL of human normal plasma.Human normal plasma is prepared by pooling plasma units from not fewer than 30 donors and storing at − 30 °C or lower.The estimated potency is not less than 0.2 units/mL.The confidencelimits (P = 0.95)are not less than 80 per cent and not more than 120 per cent of the estimated potency.Activated partial thromboplastin time (APTT).Use an apparatus suitable for measurement of coagulation times or perform the assaywith incubationtubes maintainedin a water-bath at 37 °C.Place in each tube 0.1 mL of thepreparation to be examined and 0.1 mL of a suitable APTT reagent (containing phospholipid and contact activator),both previously heated to 37 °C,and incubate the mixture for a recommended time at 37 °C.To each tube add 0.1 mL of a3.7 g/L solution of calcium chloride R previously heated to 37 °ing a timer,measure the coagulation time,i.e.theinterval between the moment of the addition of the calciumchlorideand the 1stindication of the formation of fibrin,whichmay be observed visually or by means of a suitable apparatus.The volumes given above may be adapted to the APTT reagent and apparatus used.The coagulation time complies with the approved specification for the product.LABELLINGThe label states:–the ABO blood group;–the method used for virus inactivation.01/2014:2387corrected 11.0HUMAN α-1-PROTEINASE INHIBITORα-1-Proteinasi inhibitor humanum DEFINITIONSterile liquid or freeze-dried preparation of a plasma proteinfractioncontaining mainly human α-1-proteinase inhibitor (also known as human α-1-antitrypsin or α-1-antiproteinase).Human α-1-proteinase inhibitor is a glycoprotein existing in isoforms with different isoelectric points and is the most abundant multifunctional serine proteinase inhibitor in human plasma.It is obtained from human plasma that complies with the monograph Human plasma for fractionation (0853),using asuitable fractionation process and further purification steps.Other plasma proteins may be present.The preparation maycontain excipients such as stabilisers.PRODUCTIONGENERAL PROVISIONSThe method of preparation is designed to maintain functional integrity of α-1-proteinase inhibitor.It includes a step or steps that have been shown to remove or to inactivate known agents of infection.The subsequent purification procedure must be validated to demonstrate that the concentration of any substances used for inactivation of viruses during production is reduced to a suitable level and that any residues are such as not to compromise the safety of the preparation for patients.The specific activity is not less than 0.35 mg of active human α-1-proteinase inhibitor per milligram of total protein.The ratio of human α-1proteinase inhibitor activity to human α-1-proteinase inhibitor antigen is not less than 0.7.No antimicrobial preservative or antibiotic is added.The solution is passed through a bacteria-retentive filter and distributed aseptically into the final containers.It may be subsequently freeze-dried.General Notices (1)apply to all monographs and other texts 3007。
阿斯顿发违法
Electrochimica Acta 53(2008)5653–5659Contents lists available at ScienceDirectElectrochimicaActaj o u r n a l h o m e p a g e :w w w.e l s e v i e r.c o m /l o c a t e /e l e c t a c taElectrochemical characterisation of patterned carbon nanotube electrodes on silane modified siliconBenjamin S.Flavel,Jingxian Yu,Joseph G.Shapter ∗,Jamie S.QuintonSchool of Chemistry,Physics &Earth Sciences,Flinders University,Sturt Road,Bedford Park,Adelaide,SA 5001,Australiaa r t i c l e i n f o Article history:Received 24October 2007Received in revised form 11February 2008Accepted 4March 2008Available online 18March 2008Keywords:Silicon NanotubesAtomic force anodisation lithography Patterned attachment Cyclic voltammetrya b s t r a c tPreviously we have used atomic force anodisation lithography,with a self-assembled monolayer of hex-adecyltrichlorosilane as a resist,to pattern silicon oxide nanostructures onto a p-type silicon (100)substrate.A condensation reaction was used to immobilise carbon nanotubes with high carboxylic acid functionality directly to the silicon oxide.A further condensation reaction using this surface attached the molecule ferrocenemethanol to the bound nanotubes.These new nanostructures were used as elec-trodes to observe the oxidation and reduction of ferrocene.However,because the small currents measured are near the detection limits of the electrochemical system used,important electrode kinetics could not to be obtained.A scribing approach made larger regions of oxidised silicon leading to the creation of larger scale patterned arrangements of carbon nanotubes allowing measurement of important electro-chemical parameters such as electrode kinetics,electron transfer rates and surface concentration of redox molecules.Knowledge of these characteristics has provided insights into the behaviour of the microelec-trodes created using atomic force microscopy.©2008Elsevier Ltd.All rights reserved.1.IntroductionCarbon electrodes have been widely employed in the field of electro-analysis due to their low background current,wide poten-tial window,chemical inertness and low cost [1].There are many different forms of carbon suitable for the development of an elec-trode surface such as graphite,carbon fibres,porous carbon and glassy carbon,however,one of the most promising is carbon nan-otubes [1–7].Since their discovery,carbon nanotubes have received considerable attention due to their remarkable electrical,chem-ical,mechanical and structural properties [2].These electronic properties suggest that carbon nanotubes might be able to medi-ate electron transfer reactions with a wide range of biological and environmentally significant electro-active species [1,8].It is believed that this may provide a new avenue for the development of electrochemical sensors [9].Currently one of the limiting factors impeding the large-scale development of such molecular sensors,in particular biosensors,is the unacceptably low sensor-to-sensor reproducibility and poor signal stability [10].Carbon nanotubes have exhibited superior performance to other carbon surfaces [3]due to their very stable electrochemical behaviour [1]and have already been used to catalyse the electro-chemical reaction of such molecules as dopamine [11],cytochrome∗Corresponding author.Tel.:+61882012005.E-mail address:joe.shapter@fl.au (J.G.Shapter).c [12],NADH [8],proteins [3]and hydrazine compounds [8].For example,Santhanam et al.[11]have reported a high degree of reversibility in the oxidation of dopamine using a carbon nanotube electrode without any pre-treatment to induce surface activa-tion.Li et al.[12]have modified glassy carbon electrodes with single-walled carbon nanotubes and were able to obtain a pair of well-defined redox waves by placing the electrode in a cytochrome c aqueous solution.This was found to be a diffusion limited pro-cess and had a detection limit down to 1.0×10−5M.Furthermore,Gooding et al.[3]have attached a small redox protein obtained from the digestion of cytochrome c to the free end of carbon nanotubes immobilised to a gold surface with alkanethiols.The high electron transfer rate (between 1and 20s −1)observed demonstrates a good electrical communication between the underlying electrode sur-face and redox proteins [3,13]using carbon nanotubes.Li et al.[14]have also investigated the electrochemical properties of capaci-tance and electron transfer rate of a variety of carbon nanotube ensembles using the ferrocene redox couple as a bench mark where it was found that the density and purity of carbon nanotubes is of crucial importance for sensor/electrode applications.Similarly,we have previously investigated the electron transfer rate of single-walled carbon nanotubes chemically attached to silicon wafers using the ferrocene redox couple and have not only suggested that these systems could be used for sensor applications but also for the integration into silicon-based molecular electron-ics to create molecular memory devices [4,15].It is important to investigate fundamental properties of carbon nanotube-based0013-4686/$–see front matter ©2008Elsevier Ltd.All rights reserved.doi:10.1016/j.electacta.2008.03.0225654 B.S.Flavel et al./Electrochimica Acta53(2008)5653–5659electrodes,such as background,capacitance,and electron transfer rate[14]as the electrochemical behaviour of carbon nanotubes still remains to be fully characterised[10].It is also important that this characterisation represents the ensemble configuration [14]as the interaction of the carbon nanotube with each system will be different and will hence allow for the potential application of each electrode to evaluated.One technique used extensively in the literature to characterise such electrode systems is cyclic voltammetry[1–4,8–12,14]due to the simplicity of the technique and well-understood theory[16].In this work we present an investigation into the kinetics and electron transfer rates of single-walled carbon nanotubes directly attached to silicon substrates in a surface patterned arrangement. Previously we have reported the fabrication of patterned carbon nanotube electrodes[17,18]utilising a scanning probe method called anodisation lithography.This technique allows user-defined regions of silicon oxide to be created within a self-assembled mono-layer of hexadecyltrichlorosilane on silicon substrate surfaces. Afterward,single-walled carbon nanotubes with high carboxylic acid functionality are directly attached via a condensation reac-tion.Two different electrodes were created.Thefirst consisted of immobilised carbon nanotubes on a patterned substrate,whereas the second electrode comprised the redox-active molecule fer-rocenemethanol immobilised on the carbon nanotube surface using further condensation[17].The electron transport proper-ties of these architectures may be examined via the observation of the well-known oxidation and reduction of ferrocene using cyclic voltammetry in a ferrocene or supporting electrolyte solu-tion respectively,with the substrate surface as the point of electrical contact.2.Materials and methods2.1.Preparation of electrodesThe preparation of carbon nanotube electrodes using the atomic force microscope has been described in detail previously[17,18]. In brief a p-type silicon(100)(Virginia Semiconductor,A) surface was hydroxylated in a1:3(v/v)mixture of30%H2O2(Chem-Supply,South Australia)and98%H2SO4(Labscan Asia Co.Ltd., Thailand).The hydroxyl-terminated silicon wafers were immersed into a0.5%solution of90%hexadecyltrichlorosilane(Fluka Produc-tion GmbH)in99%hexadecane(Sigma–Aldrich)for40min.The substrate was rinsed in chloroform(Ajax-Finechem)and allowed to dry.Atomic force anodisation lithography was then used to pattern the silicon substrate by selective oxidation of the hexadecyl-trichlorosilane layer to form controllable,well defined,nanoscale silicon oxide surface structures.By treatment of the silicon oxide structures with a1:1:5solution of30%NH4OH(Sigma–Aldrich), 30%H2O2(Chem-Supply,South Australia)and water followed by a1:1:5solution of36%HCl(Ajax FineChem),30%H2O2and water, hydroxyl groups were introduced to the patterned oxide surface. To these now hydroxyl-terminated silicon oxide structures,single-walled carbon nanotubes,with high carboxylic acid functionality, can be directly attached using a condensation reaction supported by the coupling agent N,N -dicyclohexylcarbodiimide(DCC)(Fluka Production GmbH).Single-walled carbon nanotubes(Carbon Solutions Inc.,CA,USA, RFP-SWNT)were functionalised with carboxylic acid groups as previously described[4,17–19]using a3:1,v/v solution of98% H2SO4and70%HNO3under ultrasonication.Upon attachment to the silicon oxide a pattern of vertically aligned carbon nanotubes is obtained as shown in Fig.1.This substrate can be used as an elec-trode without further modification.Additionally,thenanotubes Fig.1.AFM image of carbon nanotubes directly attached via an ester linkage to a patterned electrode created by atomic force anodisation lithography.still have carboxylic acid functionality available after attachment which can then be used to further modify the nanotubes.In this case,ferrocenemethanol was attached to the carboxylic acid end groups of the carbon nanotube using another condensation reaction.The attached carbon nanotube substrate was immersed in3mL of99.9%dimethyl sulfoxide(Sigma–Aldrich)containing 0.3mg of99.0%N,N -dicyclohexylcarbodiimide and1.5mg of97% ferrocenemethanol(Sigma–Aldrich)for48h at25◦C.The substrate was then rinsed in acetone and dried with nitrogen.However,as can be seen in Fig.1,the active electrode surface area of these electrodes is approximately5m2hence the ability to measure electrochemical current from an individual electrode is very dif-ficult.Previously the silicon substrate was repeatedly patterned with the atomic force microscope to create an electro-active region of approximately300m2to obtain a current that is detectable with our electrochemical system.To increase the measured electro-chemical current further to a level where electrochemical analysis is possible,a silicon carbide scribe was lightly drawn across the surface,scratching the silicon/silane substrate.This substrate was used immediately although it is exposed briefly to air resulting in a thin oxide being formed in the scratched region.This scratched region typically had an area of approximately5000m2and using the same chemistry for the electrodes created with atomic force microscopy,carbon nanotubes could also be directly attached. 2.2.Atomic force microscopy(AFM)Atomic force microscope images were taken in air with a multi-mode head and Nanoscope IV controller,Digital Instruments, Veeco,Santa Barbara,operating in tapping mode using commer-cially available silicon cantilevers(FESP-ESP series,Veeco,Santa Barbara)with fundamental resonance frequency between70and 85kHz.Topographic(height)and amplitude images were obtained simultaneously at a scan rate of1Hz with the parameters set point,amplitude,scan size and feedback control optimised for each sample.Surface patterning using an atomic force microscope cantilever has been explained in detail previously[17,18].Briefly, anodisation lithography was conducted in tapping mode with a platinum/iridium-coated silicon cantilever(SCM-PIT series,Veeco, Santa Barbara)with an applied cantilever voltage of−11V and tip velocity of1m s−1.Prior to patterning the amplitude set point was reduced to70%of its original value to reduce the tip-substrate distance and atmospheric humidity levels were used.Images pre-B.S.Flavel et al./Electrochimica Acta53(2008)5653–56595655sented represent background subtracted data using theflatten feature in the WSxM[20]software.2.3.ElectrochemistryElectrochemical measurements were performed with a BAS100B Electrochemical Analyser(Bioanalytical Systems Inc., USA),operating in cyclic voltammetry mode using a specially designed electrochemical cell[15].All data was collected using the BAS100W(Bioanalytical Systems Inc.,USA)software v2.3 with data presented representing a Fourier transform of the raw signal.The background capacitive current was subtracted using the UTLIS,Utilities for Data Analysis software(Dirk Heering). Two different electrochemical experiments were carried out,one with the use of un-modified ferrocenemethanol carbon nanotube electrodes and the second with ferrocenemethanol modification. In the un-modified situation,an electrolyte solution containing 1mmol L−198%Ferrocene(Sigma–Aldrich)and1mmol L−1of 98%tetrabutylammonium perchlorate(Fluka)in acetonitrile (Scharlau Chemie)was used.For the ferrocenemethanol modified carbon nanotube electrodes an electrolyte solution containing 1mmol L−1of98%tetrabutylammonium perchlorate in acetoni-trile was used.The potential was swept initially in the anodic direction from100to900mV at scan rates of10–3000mV s−1. Other pulsed electrochemical approaches which might lower the background were not attempted in this work as oxida-tion/reduction peak separation was important in the analysis done.3.Results and discussionIn our previous work where electrodes were created with the atomic force microscope,the patterned electrodes typically possess a small active surface area and consequently,result in a very small current measured for both the un-modified and ferrocenemethanol modified carbon nanotube structures[17].It is therefore difficult to extract information about the kinetics of the processes involved. Further to this the electrochemical current that is measured from such a small patterned region suffers from very poor signal to noise.The ability to obtain kinetic information from voltamme-try measurements requires precise knowledge of the oxida-tion/reduction current peak position and area[4,15,21,22].In the case of the AFM patterned electrodes,it is not possible to obtain this information accurately,especially in theferrocenemethanolFig.2.Cyclic voltammograms showing the scan rate dependence of(a)carbon nanotubes and(b)ferrocenemethanol modified carbon nanotubes attached directly to etched silicon regions created using the carbide scribe.Insets1and2are background-subtracted100mV s−1voltammograms for etched silicon created with carbide scribe(data shown in thisfigure)and with atomic force lithography(data previously published[17]),respectively.5656 B.S.Flavel et al./Electrochimica Acta53(2008)5653–5659modified carbon nanotube case where the measured current is just above the background noise[17].The simplest way to overcome this is to increase the current by increasing the electro-active sur-face area hence improving the signal to noise.For these electrodes this increase in active area must be accomplished by attaching nan-otubes to a larger area of the substrate.Due to the large amount of time required to pattern a sufficient surface area with the AFM,a silicon carbide scribe was lightly applied to remove the hexade-cyltrichlorosilane layer and expose a large underlying silicon oxide region.Whilst this approach does not afford nanoscale patterned arrays of carbon nanotubes,it is believed to be comparable to that utilising the AFM[17]and the chemical approach used to immo-bilise the carbon nanotube systems after scratching remained the same.For un-modified carbon nanotubes attached to a region created with a silicon carbide scribe in an electrolyte solution containing 1mmol L−1ferrocene and1mmol L−1tetrabutylammonium per-chlorate in acetonitrile distinct redox waves can be seen,as shown in Fig.2(a).A comparison between the electrochemical behaviour of an electrode created by a silicon scribe and the AFM can be made by considering the background subtracted voltammogram of each electrode obtained at a scan rate of100mV s−1.The anodic and cathodic peak positions for an electrode created with the scribe(see inset A1)were found to be at voltages of505and365mV(separa-tion of140mV)with peak currents of80and−100nA,respectively. For an electrode created with the AFM(see inset A2),the peak posi-tions were found to be619and430mV(separation of189mV)with peak currents of8.2and−9.2nA,respectively.As expected increas-ing the electrode surface area from300m2for the AFM created electrode to5000m2for that of the scribe scratched electrode leads to an increase in the resulting electrochemical current.The peak separations observed for electrodes that were pat-terned with either the scribe or AFM are greater than those observed previously on unpatterned silicon.The separation in the unpatterned case compared well to a gold electrode in ferrocene solution yielding a separation of122mV[15].The increased sepa-ration is expected for the electrode created with the atomic force microscope due to the increased oxide layer thickness created from anodisation lithography[18]resulting in a slower electron transfer rate[4].In the scribe patterned case,the atmospheric exposure time of the freshly created bare Si is quite short and hence the oxide layer formed would be expected to be quite thin whilst in the unpatterned case the oxide layer is treated in situ and hence there is no exposure to the atmosphere.Thus,it is expected that the oxide layer thickness decreases in order from AFM patterned–to scribe patterned–to unpatterned substrates and this reflected in a corresponding decrease in the observed peak separation.The variation in peak separation for the patterned electrodes can also be explained in terms of contact area with the electrolyte solu-tion.For a gold electrode the contact area is a relatively homogenous smooth surface.However,for a carbon nanotube electrode,it is possible for electrical contact to be made at the carbon nanotube terminus or through the nanotube sidewalls.It has been shown that electron transfer rate along the length of the carbon nanotube is sig-nificantly faster than though the sidewalls,which are very similar to the graphite basal plane[4,14,23].The measured voltammogram from the carbon nanotube structure will represent a convolution of the two processes[4],however,the response from electron transfer through the sidewalls is expected to dominate.This is due to carbon nanotube’s one-dimensional structure[24,25]leading to dramati-cally greater‘sidewall surface area’compared to the relatively small ‘terminus surface area’.This becomes especially evident for the electrode created with the AFM due to the relatively small number of attached carbon nanotubes compared to the region createdwith Fig.3.Dependence of anodic and cathodic peak currents on scan rate for un-modified carbon nanotube electrodes.the scribe.This behaviour is not observed for carbon nanotubes attached to unpatterned silicon because in this case the electrode is covered in a‘forest’of carbon nanotubes resulting in increased ‘terminus surface area’with access to the sidewalls hindered by neighbouring nanotubes.Electrode kinetics was obtained via cyclic voltametric measure-ments at scan rates of10–1000mV s−1on a silicon carbide scribe patterned region with un-modified carbon nanotubes attached.The observed peak current was directly proportional to the square root of the scan speed as shown in Fig.3.This is a result of the semi-infinite linear diffusion of ferrocene to the carbon nanotubes and would be expected for any solution of redox-active molecules at an electrode surface.It was also found that peak separation, E p,increased with increasing scan rate,as shown in Fig.4,which is consistentwithFig.4.Dependence of peak separation on scan rate for an un-modified carbon nan-otube electrode.B.S.Flavel et al./Electrochimica Acta53(2008)5653–56595657Table1Calculation of the standard rate constant of0.1mol L−1ferrocene in0.1mol L−1TBAPsolution on single-walled carbon nanotubes attached to patterned silicon at differ-ent scan ratesScan rate(mV s−1) E p(mV)k s(cm s−1)Silicon carbide patterned area1001400.28437 4.87×10−32001410.27103 6.57×10−33001470.237697.05×10−34001560.217697.46×10−35001550.221038.47×10−36001630.204368.58×10−37001670.194368.81×10−38001740.181028.77×10−310001860.154358.36×10−3Average7.66×10−3AFM patterned area1002160.091 1.56×10−3a quasi-reversible electrochemical process and is the same asobserved in previous work using carbon nanotubes attached tounpatterned silicon[15].The standard rate constant for quasi-reversible systems can be calculated from E p using the methodof Nicholson[16,26]which introduces the dimensionless kineticparameter,«.By interpolating/extrapolating the values of«fromthe data provided by Nicholson[26],the corresponding rate con-stant can be determined from the following equation:=˛k saD O,where =D OD R1/2and a=nFRT(1)where k s is the standard rate constant(cm s−1),D O and D R are the diffusion coefficients of the oxidised and reduced states(cm2s−1),˛is the transfer coefficient and the remaining terms have their usual significance.To determine the rate constant,it is assumed that the diffusion coefficient of the ferricenium anion and cation are equivalent to ferrocene in acetonitrile,D=2.4×105cm2s−1and that˛=0.5[27].Table1shows the calculated rate constants for different scan speeds with the average calculated to be7.66×10−3cm s−1.Fora scan speed of100mV s−1,the rate constant is calculated to be4.87×10−3cm s−1.Assuming that the electrode created with AFM displays the same kinetic behaviour,an estimate for the rate con-stant for that system can also be made by applying this model to the voltammogram shown in inset A2which was measured at scan speed of100mV s−1.The rate constant for the AFM patterned sur-face was calculated to be1.56×10−3cm s−1.As expected due to the thicker oxide in the AFM case,the rate constant is lower than that for the patterned electrode created by the scribe.Previously rate constants of up to5.89×10−3cm s−1have been obtained for carbon nanotubes attached to unpatterned silicon surfaces[15]. The increase in rate constant for the unpatterned surface com-pared to scribe patterned silicon can be attributed to a thinner silicon oxide layer in the unpatterned case where the substrate is not exposed to the atmosphere during processing.The potential for patterned carbon nanotube electrodes to provide an alterna-tive to existing electrode systems can be seen upon comparison of the observed rate constant with literature values.Noel et al.[28]have used platinum,glassy carbon and polypropylene com-posite graphite electrodes in ferrocene solutions and obtained rate constants of5.1×10−3,4.5×10−3and3.3×10−3cm s−1,respec-tively which are comparable to the values obtained in this work.For the ferrocenemethanol modified carbon nanotubes attached to a region created with a silicon carbide scribe in an acetonitrile solution containing1mmol L−1of tetrabutylammonium perchlo-rate,redox waves can also be seen,as shown in Fig.2(b).Once again a comparison between the electrochemical behaviour of an electrode created by a silicon scribe and AFM can be made by considering the background subtracted voltammogram of each electrode obtained at a scan rate of100mV s−1.The anodic and cathodic peak positions for the scribe created electrode(inset B1) occur at505and369mV(separation of136mV)with peak currents of8.4and9.6nA,respectively.For the case of an electrode created via the AFM method(see inset B2),the peak positions were found to be at500and444mV(separation of56mV)with peak currents of0.2and−0.1nA,respectively.For electrodes patterned with a silicon carbide scribe,the redox peak separations observed for ferrocene in solution and ferrocene attached to the electrode are essentially identical.In contrast,for the electrode created with AFM there is a decrease in peak separa-tion of150mV upon attachment of the redox species.Previously, this dramatic decrease in separation for the AFM patterned elec-trode has been explained through consideration of the location on the carbon nanotube surface at which the electron transfer process occurs.It has been shown that the oxidation of carbon nanotubes with nitric and sulphuric acid mixtures will introduce carboxyl groups predominately at the highly reactive end caps of the car-bon nanotube[3,5,29,30]and hence it is expected that significantly more ferrocenemethanol will be immobilised in these regions.By imposing the requirement that most electron transfer occurs along the length of the carbon nanotube,the oxidation and reduction peaks would shift towards each other as such a transfer is expected to be quite efficient.This decrease in peak separation has also been observed for modified carbon nanotubes on unpatterned silicon substrates,where the peaks were seen to shift together by42mV, yielding a peak separation of80mV[4,15].It is therefore quite unexpected that in the case of the scribe patterned area that little reduction in peak separation has been observed.It is suspected that this may be due to the use of a silicon carbide scribe to create the electro-active area.These pat-terned areas are expected to be quite inhomogeneous and rough in comparison with the unpatterned and AFM patterned silicon cases (where the points of attachment for carbon nanotubes are relatively smooth).This increased roughness is expected to result in very few attached nanotubes being aligned vertically to the surface,where it may be possible for both ends of a carbon nanotube to be attached to the surface or for‘matting’to occur.In the event that both ends of the carbon nanotube are tethered to the surface,only the side-walls will be available for modification with ferrocenemethanol and hence a slower rate will be observed as previously discussed. In the case where matting of the carbon nanotubes occurs,whilst the carbon nanotube terminus is still available for attachment of ferrocenemethanol,electron exchange between the sidewalls of carbon nanotubes in contact with each other may occur hence increasing the electron pathway.Unfortunately,the depth of the scratch on the silane/silicon substrate is quite deep making AFM experiments to probe the nature of the nanotube modification on this region impossible.Once again electrode kinetics can be obtained for the fer-rocenemethanol modified carbon nanotubes electrodes by cyclic voltammetry at scan rates of10–3000mV s−1on a silicon car-bide patterned region.Oxidation and reduction peak currents were obtained from background-subtracted curves and plotted against scan rate,as shown in Fig.5(a).It can be seen that a linear rela-tionship exists between peak current and scan rate indicating that the electrochemical response measured is from surface bound electro-active species[4,31]confirming ferrocenemethanol immo-bilised on carbon nanotubes.Furthermore,the peak separation was observed to remain relatively constant with increasing scan rate as expected for a surface bound species.5658 B.S.Flavel et al./Electrochimica Acta53(2008)5653–5659Fig.5.(a)Dependence of peak current on scan rate and(b)determination of the dimensionless parameter m.The surface concentration of ferrocenemethanol molecules can thus be calculated by determining the area under the oxida-tion/reduction peaks as described by Laviron’s theory:I p=n2F2A4RT=nFQ4RT(2)where is the surface concentration(mol cm−2),A is the electro-active area(cm2),Q is the peak area of the voltammogram (C),I p is the peak current(A)and n is the number of elec-trons involved.It was determined from these measurements that there are1.14×10−9mol cm−2or6.89×1014molecules cm−2 which is10–100times greater than for ferrocene attached to directly to silicon[21].This increase in ferrocenemethanol is attributed to the increase in surface area from the attachment of ferrocenemethanol to the sidewalls and end caps of the carbon nan-otube.However,this surface concentration is slightly lower than the9.26×10−8mol cm−2or5.56×1015molecules cm−2which has been obtained in our previous work with ferrocenemethanol modified carbon nanotubes on unpatterned silicon.As discussed previously,the roughness of the substrate means that nanotubes may not be as neatly aligned as in some of our other work,which in turn means that fewer reactive sites are available and hence there is a reduction in the extent of ferrocenemethanol attachment.It is also notable that Laviron’s theory requires a precise knowledge of the electro-active area under investigation.As a result of the inhomo-geneity of the area created by the scribe,it is difficult to determine this area accurately and consequently there is a greater level of uncertainty in the calculated coverage for this surface.Assuming an electrode created with the atomic force micro-scope exhibits identical reaction kinetics,it is now possible to apply this model and determine the number of molecules attached.By considering the area under the background-subtracted oxidation peak(inset B2)the surface concentration of fer-rocenemethanol is determined to be9.59×10−8mol cm−2or 5.77×1016molecules cm−2which compares well with our previ-ous work.This increase in concentration is a result of the ability to be more precise about the electrode surface area,however it should be noted that whilst the electrode area is now known with more accuracy it is inherently more difficult to calculate the peak area accurately from such a small signal.The apparent rate constant of electron transfer of the electrode created by the scribe can also be calculated using Laviron’s method for the condition of E p<200/n mV.By considering the value of the transfer coefficient,˛,to be between0.3and0.7,the average electron transfer rate,k s,can be estimated according to the formula: k s=m nFRTwhere m is a dimensionless parameter related to the peak-to-peak separation.By using the slope from a plot of =f(m−1),as shown in Fig.5(b),m was determined and hence k s found to be15.6s−1.The apparent rate constant of electron transfer for ferrocene attached to carbon nanotubes on unpatterned silicon and ferrocene directly attached to silicon has been found to be21and104s−1,respec-tively.The decrease in electron transfer rate compared to ferrocene directly attached to silicon is attributed to several factors.Firstly, the increased separation of the redox-active species from the sub-strate upon attachment to a carbon nanotube will dramatically reduce the electron transfer rate.Secondly,there is also a significant difference in electron transfer rates along the length and through the sidewalls of a carbon nanotube with the measured electron transfer rate in the nanotubes cases representing a convolution of these processes.The small decrease in electron transfer rate for the ferrocenemethanol modified carbon nanotubes on the scribe pat-terned surface compared to the unpatterned silicon is attributed to the inhomogeneous silicon oxide layer which is created upon sur-face patterning with the scribe leading to a poorer quality nanotube electrode.4.ConclusionThis work has provided a detailed analysis of the electrochemi-cal and kinetic parameters of patterned carbon nanotube electrodes on a silane modified silicon substrate.For carbon nanotube elec-trodes in a ferrocene solution,the redox process was determined to be diffusion limited with a standard rate constant of7.66×10−3 and1.56×10−3cm s−1for an electrode created with a scribe and AFM,respectively.The decrease in rate constant for the AFM fab-ricated electrode was attributed to the increase in silicon oxide thickness on the surface.Cyclic voltammetry for the chemically modified nanotube electrodes demonstrated that the signal was due to surface bound redox species.The number of surface bound ferrocenemethanol molecules was calculated to be6.89×1014and 5.77×1016molecules cm−2for an electrode created with a scribe and AFM,respectively.This represents a dramatic increase com-pared to ferrocene directly attached to silicon.The average electron transfer rate for this system was determined to be15.6s−1.With the knowledge of these important electrochemical characteristics it may be possible for these electrodes to be integrated into silicon-based molecular electronic devices and sensors.In particular the attachment of redox-active molecules such as ferrocenemethanol to defined carbon nanotube structures has significant potential in thefield of molecular memory.。
英文文献翻译(聚硅氯化铝的电动特性凝固行为)
聚硅氯化铝( PASiC )的电动特性凝固行为(北京大学环境工程学院,环境科学与工程系,山东大学,济南250100 Email : bygao @sdu. edu. cn)摘要:电动特性和凝固行为的聚硅氯化铝(PASiC)和聚合氯化铝(PAC)进行了研究,并比较了流动电流(SC)的测量和JAR测试方法。
实验结果表明,相比较PAC,聚硅酸与带负电荷的铝水解产物相互作用减少了PASiC 电荷中和能力。
聚硅氯化铝(PASiC)盐基度(B)和Al / Si摩尔比的减少有着密切的关系。
聚硅氯化铝(PASiC)的电荷中和能力随B值和Al / Si摩尔比的降低而降低。
与此相反,制备工艺也会影响聚硅氯化铝(PASiC)的电荷中和能力。
此外,对比聚合氯化铝,聚硅氯化铝(PASiC)有更好的絮凝效果。
关键词:絮凝剂聚合氯化铝(PASiC);流动电流(SC);电动特性;混凝效果。
引言无机高分子絮凝剂在水和废水处理的絮凝过程一般涉及两个方面:一方面是研究水解聚合过程,物质在水中转化成无机金属盐,而另一方面是研究胶体粒子在水解过程中的不稳定因素。
因为在水中增加絮凝剂后胶体粒子与电荷密度是密切相关的,絮凝剂本身的不稳定电动特性是一个重要的的研究方面。
目前,调查电动特性和判断絮凝效果的方法有两个,分别是流动电流(SC)和微电脉测量技术(Black , 1965 ; Tang , 1995)。
微电泳测量技术是观察带电粒子在电场的时间速度后计算出Zeta电位的胶体粒子。
Zeta电位是一个重要的参数来表明胶体的电动特性,它可以被视为一种有效的指标来判断水中胶体粒子在加入絮凝剂后的破坏程度,也对观察絮凝剂的絮凝效果有所帮助。
然而,测量Zeta电位也存在着以下缺点:低精度,可重复性差,并且不能被用于在线监测和连续检测。
为了克服这些缺点,最近SC被广泛用于调查絮凝剂表面上胶体粒子的电动特性和电荷中和能力(Qu , 1997),此外, Zeta电位反映的电荷中和能力为胶体分散,被称为分离弥漫层,而SC所研究的结果是分离弥漫层和固定层。
电子科学与技术专业外语翻译
Figure 1-1】图1-1 给出了在三种材料中一些重要材料相关的电阻值(相应电导率ρ≡1/δ)。
However】然而锗不太适合在很多方面应用因为温度适当提高后锗器件会产生高的漏电流。
For a given】对于给定的半导体,存在代表整个晶格的晶胞,通过在晶体中重复晶胞组成晶格。
This structure】这种结构也属于金刚石结构并且视为两个互相贯穿的fcc亚点阵结构,这个结构具有一个可以从其它沿立方对角线距离的四分之一处移动的子晶格(位移/4)Most of】多数Ⅲ-Ⅴ半导体化合物具有闪锌矿结构,它与金刚石有相同结构除了一个有Ⅲ族Ga原子的fcc子晶格结构和有Ⅴ族As原子的另一个。
.For example】例如,孤立氢原子的能级可由玻尔模型得出:式中m0 代表自由电子质量, q是电荷量,ε0是真空中电导率, h 是普朗克常数,n 是正整数称为主量子数。
Further decrease】空间更多减少将导致能带从不连续能级失去其特性并合并起来,产生一个简单的带。
As shown】如图1-4(a)能带图所示,有一个大带隙。
注意到所有的价带都被电子充满而导带中能级是空的As a consequence】结果,半满带的最上层电子以及价带顶部电子在获得动能(外加电场)时可以运动到与其相应的较高能级上At room】在室温和标准大气压下,带隙值硅(1.12ev )砷化镓(1.42ev)在0 K带隙研究值硅(1.17ev )砷化镓(1.52ev)Thus】于是,导带的电子密度等于把N(E)F(E)dE从导带底Ec (为简化起见设为0)积分到导带顶EtopFigure 1-5】图1-5从左到右示意地表示了本征半导体的能带图, 态密度(N(E)~E1/2), 费米分布函数, 本征半导体的载流子浓度In an extrinsi c】在非本征半导体中,一种载流子类型增加将会通过复合减少其它类型的数目;因此,两种类型载流子的数量在一定温度下保持常数For shallow】对硅和砷化镓中的浅施主,在室温下,常常有足够的热能电离所有的施主杂质,给导带提供等量的电子We shal l】我们先讨论剩余载流子注入的概念。
电絮凝在水处理中的应用
电絮凝在水处理中的应用絮凝是水处理过程最重要的物理化学操作过程之一,这一过程通常是脱稳和使小颗粒物凝聚成大颗粒。
目前,化学絮凝的可接受程度正逐渐变小,这主要是因为与化学试剂处理有关费用昂贵(如:产生污泥的体积大,产生有毒废物,昂贵化学药剂等),而絮凝过程可通过化学和电学途径即电絮凝技术而获得。
1 电絮凝的理论基础电絮凝一个复杂的过程,在电场的作用下金属电极产生阳离子在进入水体时包括许多物理化学现象,从离子的产生到形成絮体包括三个连续的阶段:(1)在电场的作用下,阳极产生电子形成“微絮凝剂”——铁或铝的氢氧化物;(2)水中悬浮的颗粒、胶体污染物在絮凝剂的作用下失去稳定性;(3)脱稳后的污染物颗粒和微絮凝剂之间相互碰撞,结合成肉眼可见的大絮体。
由于电絮凝过程中电解反应的产物只是离子,不需要投加任何氧化剂或还原剂,对环境不产生或很少产生污染,被称为是一种环境友好水处理技术。
电絮凝法具有很多的优点,如:(1)设备简单,占地面积少,设备维护简单;(2)电絮凝过程中不需要添加任何化学药剂,产生的污泥量少,且污泥的含水率低,易于处理;(3)操作简单,只需要改变电场的外加电压就能控制运行条件的改变,很容易实现自动化控制;电絮凝法中常用的电极材料为铝和铁,在阳极和阴极之间通以直流电,发生的电极反应如下:铝阳极Al-3e→Al3e+ (1)在碱性条件下Al3e++3OH-→Al(OH)3 (2)在酸性条件下Al3e++3H2O→Al(OH)3+3H+(3)铁阳极Fe-2e→Fe2e+ (4)在碱性条件下Fe2e++2OH-→Fe(OH)2 (5)在酸性条件下4Fe2e++O2+2H2O→4Fe3e++4OH-(6)另外,水的电解还有氧气放出2H2O-4e→O2+4H+(7)在阴极发生如下反应2H2O+2e→H2+2OH-(8)电絮凝法在处理过程中具有多功能性,除了电絮凝作用之外还有电化学氧化和还原、电气浮等作用。
电絮凝法去除水中污染物过程见图1。
美国医院里很喜欢用缩写
美国医院里很喜欢用缩写,看得人头昏脑胀。
尤其有的医生写的缩写想破了脑袋也想不出来。
比如TKO,各位想想什么意思?是输液时用的--to keep open,就是只要维持输液通畅就行,速度当然要慢了。
偶尔在一个网站上看到了比较全面的医学缩写,但是很多,要全部记下来对我来说太难了,所以我准备打印下来带在身上,上班的时候不懂就可以查一查,省得去问别人了。
各位有兴趣不妨看看,也许以后工作中能用上。
[edit] AA&Ox3 Alert and Oriented to person, place, and timeAlert and Oriented to person, place, time, andA&Ox4circumstances(often used interchangeably with A&Ox3) A&W Alive and wella.a. of each, from Latin, anaAAA Abdominal aortic aneurysm, Pronounced "Triple A"AAT activity as toleratedAb AntibodyABC aspiration biopsy cytology"Asymmetry, borders, color, diameter" features on ABCDconsidering "is it a Melanoma"?ABD or abd abdomenABG Arterial blood gasesABMT Autologous bone marrow transplantationABPI Ankle brachial pressure indexdoxorubicin bleomycin vinblastine dacarbazine ABVDFirst-line treatment for Hodgkin's lymphoma. ABX antibioticsa.c. before food, from Latin, ante cibumACE Angiotensin converting enzymeACEI Angiotensin converting enzyme inhibitorsAch AcetylcholineACL Anterior cruciate ligamentACLS Advanced cardiac life supportACTH Adrenocorticotropic hormonead. make up toad part. dolent to the painful parts, from Latin, partes dolentes AD Alzheimer's DiseaseADA Adenosine deaminaseADC AIDS dementia complexADD Attention Deficit DisorderADH Antidiuretic hormoneADHD Attention Deficit Hyperactivity DisorderADL activities of daily livingad lib as desired from Latin, ad libitumadm admissionADR Adverse drug reactionAEM Ambulatory electrocardiogram monitoringAF atrial fibrillationAF atrial flutterAF Amniotic fluidAFB acid fast bacilliAFO ankle-foot orthosisAFP Alpha-fetoproteinAg AntigenAGA Anti-gliadin Antibodiesa.h. every other hour, from Latin, alternis horis AHF Antihemophilic factorAHG Antihemophilic globulinAHH aryl hydrocarbon hydroxylaseAI Artificial inseminationAI Aortic insufficiencyAICD Automated implantable cardioverter-defibrillator AID Artificial insemination by donorAIDS Acquired Immune Deficiency SyndromeAIH artificial insemination by husbandAIIRB Angiotensin II receptor antagonistaka also known asAKA Above knee amputationALG Antilymphocytic globulinALL Acute lymphocytic leukemiaALP Alkaline phosphataseALPS Autoimmune lymphoproliferative syndromeALS Amyotrophic Lateral SclerosisALS Advanced Life SupportALT Alanine transferasealtern. d. every other day, from Latin, alterno die AMA Anti-mitochondrial AntibodiesAMA Against Medical AdviceAMA Advanced Maternal Age (35 years or greater) AMC Arthrogryposis multiplex congenitaAMI Acute myocardial infarctionAML Acute myelocytic leukemiaAMP Adenosine monophosphateAMS Acute mountain sicknessAMS atypical measles syndromeANA Anti-nuclear antibodyANCA Anti-neutrophil cytoplasmic antibodiesANF Atrial natriuretic factorANP Atrial natriuretic peptideANS Autonomic nervous systemANUG Acute necrotizing ulcerative gingivitisa.p. before dinner, from Latin, ante prandiumAP Alkaline phosphataseacetaminophen, paracetamol; from the chemical name APAPN-acetyl-para-aminophenolAPD adult polycystic diseaseAPECED autoimmune polyendocrinopathyAPH Antepartum haemorrhageAPLS antiphospholipid antibody syndromeapplic. allicandus, from Latin, to be appliedAPSAC Anisoylated plasminogen streptokinase activator complex APS autoimmune polyglandular syndromeaPTT Activated Partial Thromboplastin Timeaq. water, from Latin, aquaaq. bull. boiling water, from Latin, aqua bulliensaq. calid. warm or hot water, from Latin, aqua calidaaq. dist. distilled water, from Latin, aqua distillataaq. gel. cold water, from Latin, aqua gelidaAR Aortic RegurgitationARB Angiotensin II receptor antagonistARC AIDS related complexARDS Acute respiratory distress syndromeARF Acute renal failureArg ArginineART antiretroviral therapyART assuming room temperature, ie) the patient has died.ARM Artificial rupture of membranesASA Acetylsalicylic acid - commonly known as aspirinAS Aortic stenosisASCAD arteriosclerotic coronary artery diseaseASD Atrial septal defectAtypical squamous glandular cells of undetermined ASGUSsignificanceASCUS Atypical squamous cells of undetermined significance ASL American sign languageASO Antistreptolysin OASOT Antistreptolysin O titreAST Aspartate transaminaseASX AsymptomaticATA Anti-transglutaminase antibodiesATCC American Type Culture CollectionATG Antithymic globulinAT-III Antithrombin IIIATP acute thrombocytopenic purpuraATP adenosine triphosphateATP Anti-tachycardia pacingaur. ear, from Latin, aurisaur. dextro. to right ear, from Latin, auris dextraeaur. laev to left ear, from Latin, auris laevaeaurist. ear drops, from Latin, auristillaeAVM Arteriovenous malformationAVR Aortic valve replacementAZT azidothymidineBa BariumBAL Bronchoalveolar lavageBAL British anti-LewisiteBAL Blood Alcohol LevelBAO Basic acid outputBAT Brown adipose tissueBCG Bacille Calmette-Guerin (a tuberculosis vaccination) BCX Blood cultureBBMF "Bone break, me fix" Orthopedic consent formb.d. Twice daily, from Latin, bis dieb.i.d. Twice daily, from Latin, bis in dieBE Base excessBGL Blood Glucose LevelBIBA brought in by ambulanceBIB Brought in byBK Bacterium KochBKA Below Knee Amputationbl.cult Blood culturebld BloodBLS Basic Life SupportBMC Bone mass contentBMD Bone mineral density (also termed bone mass measurement) BMI Body mass indexBMP Blood Metabolic ProfileBMR Basal metabolic rateBMT Bone marrow transplantationBNF British National FormularyBNP Brain natriuretic peptideBOA Born out of AsepsisBOI Born on island, ie. a local patient.BOOP Bronchiolitis obliterans organizing pneumoniaBP Blood pressureBP Bipolar disorderBPAD Bipolar Affective DisorderBPD Bi-Parietal DiameterBPD Borderline personality disorderBPH Benign prostatic hyperplasiaBPM Beats per minuteBPPV Benign paroxysmal positional vertigoBRAT Bananas, Rice, Applesauce, (dry) Toast: acronym for blanddietBananas, Rice, Applesauce, (dry) Toast, Yogurt: acronym for BRATYbland diet for childrenBRP Bathroom PrivilegesBRBPR Bright red blood per rectumBS Breath or Bowel sounds on auscultation with stethoscope BS Blood SugarBSE Bovine spongiform encephalopathyBSE Breast self-examinationBSL Blood Sugar LevelBSP BromsulphthaleinBUN Blood urea nitrogenBV Bacterial vaginosisBx Biopsyc (c with a bar over it) with, from Latin, cumCABG Coronary Artery Bypass Graft surgery. Pronounced "Cabbage". CAD Coronary artery diseaseCAG Coronary Artery GraftcAMP cyclic adenosine monophosphateCA Carcinoma, CancerCa CalciumCerebral Autosomal Dominant Arteriopathy with Subcortical CADASILInfarcts and LeukoencephalopathyCAH Chronic Active HepatitisCAH Congenital adrenal hyperplasiaCAT Computed axial tomographyCAPD Continuous ambulatory peritoneal dialysisCBC Complete Blood CountCC Cubic centimenter, or Chief ComplaintCCF Congestive cardiac failureCCK CholecystokininCEA Carcinoembryonic antigenCF Cystic fibrosiscGMP Cyclic guanosine monophosphateChE CholinesteraseCHD Coronary heart diseaseCHE CholinesteraseCHF Congestive heart failureCI Confidence intervalCJD Creutzfeldt-Jakob diseaseCK Creatine kinaseCKD Chronic kidney diseaseCLL Chronic lymphocytic leukemiaCML Chronic myelogenous leukemia also called Chronic myeloidleukaemiaCMML Chronic myelomonocytic leukemiaCMS Chronic mountain sicknessCMV CytomegalovirusCNS Central nervous systemCOAD Chronic obstructive airways diseaseCOLD Chronic obstructive lung diseaseCOPD Chronic obstructive pulmonary diseaseCO Cardiac outputCO, C/O Complains Of...CO Carbon monoxideCarbon dioxideCO2COX-1 Cyclooxygenase 1COX-2 Cyclooxygenase 2CP cerebral palsyCP Chest PainCPAP Continuous positive airway pressureCPK Creatine phosphokinaseCPR Cardiopulmonary resuscitationCREST Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae CRF Chronic renal failureCRF Corticotropin-releasing factorCRH Corticotropin-releasing hormoneCRI Chronic renal insufficiencyCRP C-reactive proteinCR Complete remissionCS Caesarean sectionCsA Ciclosporin ACSF Cerebrospinal fluidCT computed axial tomographyCTX ceftriaxone, a third-generation cephalosporin antibiotic CVA Cerebrovascular accidentCVC Central venous catheterCVD Cardiovascular diseaseCVP Central venous pressureCVS Chorionic villus samplingCVID Common variable immunodeficiencyCx Microbiological cultureCXR Chest X-rayDA DopamineDBP Diastolic blood pressureD&C Dilatation and curettageDCBE Double Contrast Barium EnemaDCM Dilated cardiomyopathyDDD Daily Defined DosesDDx Differential diagnosisDEXA Dual Energy X-ray AbsorptiometryDHE DihydoergotamineDHEA-S Dehydroepiandrosterone sulphateDIB Dead in BedDIC Disseminated intravascular coagulationDIP Distal interphalangeal jointDiPerTe Diphtheria Pertussis TetanusDiTe Diphtheria TetanusDJD Degenerative Joint DiseaseDKA Diabetic Keto-AcidosisDPT Diphtheria Pertussis TetanusDM Diabetes MellitusDNA Deoxyribonucleic acidDNI Do Not IntubateDNR Do Not ResuscitateDNAR Do Not Attempt ResusciatationDOA Dead on arrivalDOB Date of birthDOE Dyspnea on exertionDocusate sodium; from the chemical name dioctyl sodium DOSSsulfosuccinateDT Diphtheria TetanusDTP Diphtheria Tetanus PertussisDUB Dysfunctional uterine bleedingDVT Deep vein thrombosisDx DiagnosisE EcstacyE ElectrolytesEACA Epsilon-aminocaproic acidEBM Evidence-based medicineEBM Expressed Breast MilkEBV Epstein-Barr virusEC Enterically CoatedECG ElectrocardiogramECMO Extracorporeal membrane oxygenationED Emergency departmentED Erectile DysfunctionED Ectodermal dysplasiaEDC Estimated Date of Confinement (at 40/40 weeks of pregnancy) EDD Estimated Date of Delivery (at 40/40 weeks of pregnancy) EDD Estimated date of dischargeEDRF Endothelium-derived relaxing factor aka Nitric oxideEEG ElectroencephalogramEF Ejection FractionEGF Epidermal Growth FactorEKG ElectrocardiogramELLSCS Elective Lower Segment Caesarian SectionELISA Enzyme-Linked Immunosorbent AssayEMC EncephalomyocarditisEMD Early Morning DiscoveryEMD ElectroMechanical DissociationEMF Endomyocardial fibrosisEMG ElectromyographyEMLSCS Emergency Lower Segment Caesarian SectionEarly Morning Urine sample (being the most concentrated EMUgenerally used for pregnancy testing)ENT Ear Nose and Throat. (Otolaryngology)EENT eyes, ears, nose, throatEOM Extra ocular musclesEOMI Extra ocular movements intactEPH Edema Proteinuria HypertensionEPO ErythropoietinERCP Endoscopic Retrograde CholangiopancreatographyExtracorporeal Shockwave Lithotripsy (also ESWL) - see ESLlithotriptorESBL Extended Spectrum Beta-Lactamase gram negative bacteria ESR Erythrocyte sedimentation rateESRD End-stage renal diseaseExtracorporeal Shock Wave Lithotripsy (also ESL) - see ESWLlithotriptorET EndothelinETT Endotracheal tubeETOH ethanol or ethyl alcoholEUS Endoscopic UltrasonographyFBC Full blood countFBE Full blood examFBG Fasting blood glucoseF/C Fevers or ChillsFDIU Foetal Demise In UteroFDP Fibrinogen Degradation ProductsForced Expiratory Volume in 1 SecondFEV1Fe IronFF Free Fluids (non-thickened fluids)FFA Free fatty acidsFFP Fresh frozen plasmaFHR Fetal heart rateFHT Fetal heart tonesFHx Family HistoryFIBD Found in Bed DeadFLKFunny Looking Kid (suggesting an unspecified syndrome,should now be termed "dysmorphic features")FNA Fine Needle AspirateFNC Full nursing careFOF Found on Floor (Patient fell out of bed)FOS Full of StoolFPG Fasting plasma glucoseFSE Fetal Scalp ElectrodeFSH Follicle stimulating hormoneFTA-ABS Fluorescent Treponemal Antibody AbsorptionFTA Fluorescent Treponemal AntibodyFUBAR F***ed Up Beyond All Recognition, originally used to refer to corpses after horrendous (typically battlefield) trauma, but "FUBAR" is now sometimes used to describe very ill patients with little hope of recovery, including those that have not necessarily suffered trauma. Not very politically correct!FVCForced Vital Capacity (Spirometry test value used inassessment of Chronic obstructive pulmonary disease) FWB Full weight bearingFWD Full ward dietFx Fracture of a boneG Gravida (total number of pregnancies, successful or not) G6PD Glucose-6-phosphate-dehydrogenaseGA General anaesthesiaGABA gamma-aminobutyric acidGCA Giant cell arteritisGCS Glasgow Coma ScaleGDLH Glutamate dehydrogenaseGERD Gastroesophageal reflux diseaseGFR Glomerular filtration rateGGTP Gamma glutamyl transpeptidaseGH Growth hormoneGHRF Growth hormone releasing factorGI GastrointestinalGITS Gastrointestinal therapeutic systemGIFT Gamete intrafallopian transferGOA Gone on Arrival (i.e., DOA)Get Outta My E.R. i.e. patient who frequently presents at the GOMERER near death but manages to pull through each and every time. GOK God only knowsGORD Gastro-oesophageal reflux diseaseGOT glutamic-oxalacetic transaminaseGPT glutamic-pyruvic transaminaseGSW gunshot wound see HVLTGTN Glyceryl trinitrateGU GenitourinaryGenitourinary medicine (often used more restrictively as GUMalternative to sexually transmitted disease clinic)GvH Graft-versus-hostGvHD Graft-versus-host diseaseHA Hypertonia arterialisHAD HIV-associated dementiaH/A headacheHematoxlyn and Eosin standard tissue stain. Sometimes used H&Eas noun referring to stained slides--"H&E's showed..." HAV Hepatitis A virusHb HemoglobinHBV Hepatitis B virusHCC Hepato Cell CarcinomaHCG Human chorionic gonadotropinHCM Hypertrophic cardiomyopathyHCT HematocritHCTZ HydrochlorothiazideHCV Hepatitis C virusHDL High density lipoproteinHDL-C High Density Lipoprotein Cholesterol HDU High Dependency UnitHDV Hepatitis D virusHEENT Head Eyes Ears Nose ThroatHES Hydroxyethyl StarchHEV Hepatitis E virusHGB HemoglobinHH Hiatus herniaH&H Hemoglobin and HematocritHib Haemophilus influenzae BHIV Human immunodeficiency virusHL Hepatic lipaseHLA Human leukocyte antigensH&M Hematemesis and MelenaHOCM Hypertrophic obstructive cardiomyopathy HONK Hyperosmolar Non Ketotic ComaH&P History & PhysicalHPI History of Present IllnessHR Heart rateHRT Hormone replacement therapyH.S. At bedtime, from Latin, hora somniHSG HysterosalpingogramHSV Herpes simplex virusHT HypertensionHTLV Human T-lymphotropic virusHTN HypertensionHUS Hemolytic uremic syndromeHVLT High-velocity Lead Therapy, also see GSW (gunshot wound) Hx history (of)I131 radioactive iodineIA Intra-arterialIABP Intra-aortic balloon pumpIAI Intra-amniotic infectionIBD Inflammatory bowel diseaseIBS Irritable bowel syndromeIC IntracardiacICD Implantable cardioverter-defibrillatorICD-10 International Classification of Diseases-10th Revision ICH Intracerebral hemorrhageICP Intracranial pressureICU Intensive care unitI&D Incision and drainage (how to treat an abscess} IDA Iron deficiency anemiaIDC Idiopathic dilated cardiomyopathyIDC Indwelling catheterIDDM Insulin dependent diabetes mellitusIDL Intermediate density lipoproteinIDP Infectious Disease Precautions/ ProcessIFG Impaired fasting glycaemiaIg ImmunoglobulinIGT Impaired glucose toleranceIHD Ischaemic heart diseasei.m. intramuscularIMB InterMenstrual Bleed (bleeding between periods) IMI Intramuscular injectionINF InterferonINR International normalized ratioI&O inputs and outputsIOL Induction of laborIOL Intraocular lensIOP Intraocular pressureIP Interphalangeal jointIPPV Intermittent positive pressure ventilationIQ Intelligence QuotientISA Intrinsic Sympathomimetic ActivityISDN Isosorbide dinitrateISH Isolated systolic hypertensionISMN Isosorbide mononitratei.s.q. no change (from Latin, in status quo)IT IntrathecalITP Idiopathic thrombocytopenic purpuraITU Intensive Treatment Unit (or Intensive Therapy Unit) IUCD intrauterine contraceptive deviceIU International unitsIntrauterine Death - sometimes confused with intrauterine IUDcontraceptive device. Use FDIU or IUFDintrauterine device - sometimes confused with intrauterine IUDdeath. We now use IUCDIUFD IntraUterine Foetal DemiseIUI Intrauterine inseminationIUS IntraUterine Systemi.v. IntravenousIV-DSA Intravenous digital subtraction angiographyIVDU Intravenous drug userIVF In vitro fertilizationIVP Intravenous pyelogramIVU Intravenous urogramJMS "Junior Medical Student" AKA "MS-3" Also see "TOBASH" JVD Jugular vein distensionJVP Jugular venous pressureK Potassium (in German, Kalium)Kcal Kilocalorie, Caloriekg KilogramKIV Keep in viewKUB kidney, ureter, bladder (x-ray)L LeukocytesLABBB Left anterior bundle branch blockLAD Left Anterior Descending coronary arteryLAP Leukocyte alkaline phosphataseLAR Low Anterior ResectionLAS Lymphadenopathy syndromeLBBB Left bundle branch blockLCM Lymphocytic meningitisLDH Lactate dehydrogenaseLDL Low density lipoproteinLDL-C Low Density Lipoprotein CholesterolL-DOPA Levo-DihydrOxyPhenylAlanineLES Lower esophageal sphincterLES Lupus erythematosus systemicusLE Lupus erythematosus (in German Lupus erythematodes)leu LeukocytesLFT Liver function testLGL Lown-Ganong-Levine syndromeLGM Lymphogranulomatosis malignaLGV Lymphogranuloma venereumLH Luteinizing hormoneLIH left inguinal herniaLLL left lower lobeLLQ left lower quadrantLM Left MainLMPLast Menstrual period (prior to pregnancy and in woman withregular 28 day cycle taken as 0/40 weeks of pregnancy) LOL Little old lady ... often LOL in NADLORTA Loss Of Resistance To Air (in anesthesiology; when placing epidural, LORTA indicates entrance of needle to epidural space)LOS Length of stayLp LipoproteinLP Lumbar punctureLPL Lipoprotein lipaseLUL Left upper lobeLUQ Left upper quadrantLVEDP Left ventricular end diastolic pressureLVEF Left ventricular ejection fractionLVF Left ventricular failureLVH Left ventricular hypertrophyLV Left ventricleLVOT Left Ventricular Outflow TrackLy Lymphocyteslytes electrolytesMAO-I Monoamine oxidase inhibitorMφMacrophageMethicillin and aminoglycoside resistant Staphylococcus MARSAaureusMAS Morgani-Adams-StokesMC Metacarpal boneMCP Metacarpophalangeal jointMCHC Mean cell hemoglobin concentrationMCH Mean cell hemoglobinMicroscopy, Culture & Sensitivity, the investigation steps MC&Sin processing microbiology samplesMCV Mean cell volumeMDS Myelodysplastic syndromeMg MagnesiumMgSO4 Magnesium or Magnesium SulfateMonoclonal gammopathy of undetermined significance(unknown MGUSor uncertain may be substituted for undetermined)MI Myocardial infarctionMIC Morbus Ischaemicus CordisMIC Minimal inhibitory concentrationMLA Myelosis Leucemica AcutaMM Myeloma multiplexmod ModerateMODY Maturity onset diabetes of the youngMo MonocytesMOM Milk of magnesiaMechlorethamine, Vincristine, Procarbazine, and Prednisone MOPPin combination, older treatment for Hodgkins lymphoma. MPV Mean platelet volumeMRA Magnetic resonance angiogram or angiogrphyMRI Magnetic resonance imagingMR Mitral regurgitationMR Modified releaseMRSA Methicillin-resistant Staphylococcus aureusMS Mitral stenosisMS Multiple sclerosisMS Medical student MS-1, MS-2, MS-3, MS-4 respectivelyMSH Melanocyte stimulating hormoneMSO4 Morphine or Morphine SulfateMid Stream Urine sample (used in testing for presence of urine MSUinfections)MT Metatarsal boneMTP Metatarsalphalangeal jointMTX MethotrexateMVP Mitral valve prolapseMVPS Mitral valve prolapse syndromeNa Sodium (in German Natrium)No Abnormality Detected, i.e. the absence of abnormal signs NADon examinationNAD No apparent distress.NE NorepinephrineNe Neutrophil granulocytesNeo NeoplasmNFR Not For ResuscitationNGU Non-gonococcal urethritisNHL Non Hodgkin LymphomaNIDDM Non-Insulin Dependent Diabetes Mellitus NK Natural killer cellsNKA no known allergiesNKDA no known drug allergies. This abbreviation is also used in the military of the United States and may be printed on dog tags or a uniform.NMR Nuclear magnetic resonanceNNH Number needed to harmNNT Number needed to treatNO Nitric oxideNOF Neck of Femur Fracture (refers to Hip fracture) NOS Nitric oxide synthaseNpl NeoplasmNPO nil per os (nothing by mouth)NREM non-Rapid Eye Movementn.s. not significantNS Normal SalineNSAID Non-Steroidal Anti-Inflammatory DrugNSCC Non Squamous Cell CarcinomaNSE Neurospecific enolaseNSR normal sinus rhythmNSRI Noradrenaline-Serotonin Reuptake InhibitorNSU Non-specific urethritisNTG NitroglycerinN&V nausea & vomitingNVD nausea, vomiting & diarrheaNVD Normal Vaginal DeliveryOxygenO2OA osteoarthritisOB-GYN Obstetrics and gynecologyOCD Obsessive-compulsive disorderOD right eye from Latin, oculus dexterOD overdoseevery day, usually regarded as once daily, from the Latin, odomni die. Generally written in lower case.O/E on examinationOGTT Oral glucose tolerance testevery morning, from the Latin, omni mane. Generally written omin lower case.Otitis Media with Effusion - fluid in the inner ear without OMEother symptoms.every night, from the Latin, omni nocte. Generally written onin lower case.OP outpatient departmentOPPT Oriented to Person Place and TimeOS left eye from Latin, oculus sinisterOS Orthopedic surgeryOSA Obstructive Sleep ApneaOSH outside hospitalOTC Over-the-counter drugOTD Out the Door (discharged)OTPP Oriented to Time Place and PersonOU Both eyes, from Latin, oculi uterquep (p with a bar over it) after, from Latin, postP Parturition (total number of live births)P PhosphorusP PulsePA posterior-anteriorPA Pulmonary arteryPAF Platelet activating factorPAF Paroxysmal atrial fibrillation (meaning intermittent AF) PAH Pulmonary arterial hypertensionPAI-1 Plasminogen activator inhibitor 1PAO Peak Acid OutputPAP Papanicolaou stainPap Papanicolaou Test (pap smear)PAT Paroxysmal atrial tachycardiap.c. After food, from Latin, post cibumPCI Percutaneous coronary interventionPCL Posterior cruciate ligamentPCOS Polycystic ovarian syndromePneumocystis pneumonia (formerly Pneumocystis carinii PCPpneumonia)PCP Primary Care Physician/Primary Care ProviderPCR Polymerase chain reactionPCWP Pulmonary capillary wedge pressurePDA Patent ductus arteriosusPDE PhosphodiesterasePDT Photodynamic TherapyPE Pulmonary EmbolismPE Pre-eclampsiaPEEP Positive end expiratory pressurePEF Peak expiratory flowPEFR Peak expiratory flow ratePERLA Pupils Equal and Reactive to Light and Accommodation PERRLA Pupils Equal, Round, Reactive to Light and Accommodation PET Positron-emission tomographyPFO Patent foramen ovalePID Pelvic inflammatory diseasePIH Pregnancy induced hypertensionPIP Proximal interphalangeal jointPKA Protein kinase APKD Polycystic kidney diseasePKU PhenylketonuriaPLT plateletsPMB Post-menopausal bleeding (bleeding after menopause) [past medical history] or Perimesencephalic subarachnoid PMHhemorrhagePMN Polymorphonuclear cells, ie NeutrophilsPMR Percutaneous Myocardial RevascularisationPMR Polymyalgia RheumaticaPND Paroxysmal nocturnal dyspneap.o. By mouth (orally), from Latin, per ospoly Polymorphonuclear cells, ie NeutrophilsPOX PeroxidasePPH Post partum haemorrhagePPH Primary Pulmonary hypertensionPPROM Preterm Premature Rupture of MembranesPPTL Post-Partum Tubal Ligationp.r. per rectum (as noun: rectal examination)PRA Plasma renin activityPRIND Prolonged Reversible Ischemic Neurologic Deficitas necessary, from Latin, pro re nata(if used in chronic pain prncontrol disparagingly termed "pain relief nil")PROM Premature Rupture of MembranesPRP PanRetinal PhotocoagulationPSA Prostatic specific antigenPSP PhenylsulphtaleinPTM Pulmonary TuberculosisPatient, from Latin patiens, meaning "one who endures" or Pt."one who suffers"PTA Percutaneous Transluminal AngioplastyPTCA Percutaneous transluminal coronary angioplastyPT Prothrombin timePTH Parathyroid hormonePTx PneumothoraxPTT Partial thromboplastin timePUD peptic ulcer diseasePUVA Psoralen UV Aper vagina (as noun: vaginal examination with manual p.v.examination and speculum inspection)PVD peripheral vascular diseasePVR Pulmonary vascular resistancePWP Pulmonary Wedge PressurePx, px physical examinationPx Prognosisq each, every, {from Latin, quaque}q.a.d. every other day, (from Latin, quaque altera die) QALY Quality-adjusted life yearsq.AM every AM, (from Latin, quaque ante meridiem)q.d. each day, {from Latin, quaque die}q.d.s. four times each day, {from Latin, quater die sumendus} q.h. each hour, {from Latin, quaque hora}q.h.s. every bedtime, {from Latin, quaque hora somni}q.i.d. four times each day, {from Latin, quater in die}q.m.t. every monthq.w.k. weeklyq.o.d every other dayRA Refractory anaemiaRA Rheumatoid arthritisRAI Radioactive IodineRAPD Relative afferent pupillary defectRBBB Right bundle branch blockRBC Red blood cellsRCA Right coronary arteryRCT Randomized controlled trialREM Rapid eye movementRF Rheumatoid factorRFLP Restriction fragment length polymorphism RFT Renal function testRh Rhesus factorRhF Rheumatoid factorRIA Radioimmune assayRIBA Radioimmunoblotting assayRIMA Reversible inhibitor of monoamine oxidase A RIND Reversible ischemic neurologic deficitRLQ Right lower quadrantRNA Ribonucleic acidRNV Radionuclear VentriculographyROM Range of motionRR Respiratory rateROS Review of systemsRUQ Right upper quadrantRPR Rapid Plasma Reagin testRSV Respiratory Syncytial VirusRV Residual volumeRV Right ventricleRVF Right ventricular failureRVSP Right ventricular systolic pressureRx medical prescription or Prescription drug(s with a bar over it) without from Middle English sans, sborrowed from Old French sansSAH Subarachnoid hemorrhageSARS Severe acute respiratory syndromeSBE Subacute bacterial endocarditisSBP Systolic blood pressureSBP spontaneous bacterial peritonitiss.c. subcutaneous from Latin, subcutisSCC Squamous cell carcionaSCID Severe combined immunodeficiencySD Standard deviationSGA Small for gestational age。
电芬顿法英文
电芬顿法英文Electrochemical Fenton Process: A Promising Approach for Wastewater TreatmentThe rapid industrialization and urbanization have led to the generation of a vast array of pollutants, posing a significant threat to the environment and human health. Among the various pollutants, organic contaminants have become a major concern due to their persistence, toxicity, and potential for bioaccumulation. Conventional wastewater treatment methods often struggle to effectively remove these recalcitrant organic compounds, necessitating the development of more efficient and sustainable treatment technologies.One such promising approach is the electrochemical Fenton process, which combines the principles of electrochemistry and the Fenton reaction to achieve the degradation of organic pollutants. The Fenton reaction, named after its discoverer Henry John Horstman Fenton, involves the generation of highly reactive hydroxyl radicals (•OH) through the reaction between hydrogen peroxide (H2O2) and ferrous ions (Fe2+). These hydroxyl radicals are potent oxidizing agents capable of breaking down a wide range of organiccompounds into less harmful or even harmless substances.The electrochemical Fenton process takes the Fenton reaction a step further by integrating an electrochemical system. In this approach, the ferrous ions required for the Fenton reaction are generated in situ through the electrochemical oxidation of an iron or steel electrode. This eliminates the need for the external addition of ferrous salts, which can lead to the generation of unwanted sludge. Additionally, the electrochemical system allows for the in situ production of hydrogen peroxide, further enhancing the efficiency of the Fenton reaction.The electrochemical Fenton process offers several advantages over traditional wastewater treatment methods. Firstly, it is highly effective in the degradation of a wide range of organic pollutants, including dyes, pesticides, pharmaceuticals, and industrial chemicals. The hydroxyl radicals generated during the process are capable of breaking down complex organic molecules into simpler, less harmful compounds, ultimately leading to the mineralization of the pollutants.Secondly, the electrochemical Fenton process is a relatively simple and cost-effective technology. The in situ generation of the required reagents, such as ferrous ions and hydrogen peroxide, eliminates the need for the external addition of costly chemicals, reducing theoverall operational costs. Additionally, the process can be easily integrated into existing wastewater treatment systems, making it a versatile and adaptable solution.Furthermore, the electrochemical Fenton process is considered an environmentally friendly technology. Unlike some conventional treatment methods that may generate hazardous sludge or byproducts, the electrochemical Fenton process typically produces only innocuous end products, such as carbon dioxide and water, minimizing the environmental impact.The implementation of the electrochemical Fenton process in wastewater treatment has been the subject of extensive research and development. Numerous studies have demonstrated the effectiveness of this technology in treating a wide range of organic pollutants, including dyes, pesticides, pharmaceuticals, and industrial chemicals. The process has been successfully applied at both laboratory and pilot scales, showcasing its potential for large-scale industrial applications.One of the key factors in the successful implementation of the electrochemical Fenton process is the optimization of various operating parameters, such as pH, current density, and the concentration of reactants. Researchers have explored different electrode materials, reactor configurations, and processmodifications to enhance the efficiency and performance of the system.Additionally, the integration of the electrochemical Fenton process with other treatment technologies, such as adsorption, membrane filtration, or biological treatment, has been investigated to further improve the overall treatment efficiency and expand the range of pollutants that can be effectively removed.As the global demand for sustainable and efficient wastewater treatment solutions continues to grow, the electrochemical Fenton process emerges as a promising technology that can contribute to addressing the pressing environmental challenges. With its ability to effectively degrade a wide range of organic contaminants, its cost-effectiveness, and its environmental friendliness, the electrochemical Fenton process holds great potential for widespread adoption in the field of wastewater treatment.。
催化量eda复合物
催化量eda复合物英文回答:Catalytic amounts of EDA complexes are widely used in various chemical reactions. EDA stands for electron donor-acceptor, and these complexes are formed by the interaction between an electron donor and an electron acceptor. The electron donor is usually a Lewis base, while the electron acceptor is typically a Lewis acid.One example of a catalytic reaction using EDA complexes is the hydroboration of alkenes. In this reaction, an EDA complex of borane and tetrahydrofuran (THF) is used as the catalyst. The THF molecule acts as the Lewis base, donating a pair of electrons to the boron atom, which acts as the Lewis acid. This EDA complex activates the boron atom, making it more reactive towards the alkene substrate. The reaction proceeds through the formation of a cyclic transition state, leading to the addition of boron and hydrogen across the double bond of the alkene.Another example is the catalytic reduction of ketones using EDA complexes of borane and amines. In this reaction, the amine acts as the Lewis base, donating a pair of electrons to the boron atom, which acts as the Lewis acid. This EDA complex activates the boron atom, making it more reactive towards the ketone substrate. The reactionproceeds through the formation of a cyclic transition state, leading to the reduction of the ketone to an alcohol.The use of EDA complexes as catalysts has several advantages. First, they can be used in catalytic amounts, which means that only a small amount of the complex is needed to catalyze the reaction. This makes them cost-effective and environmentally friendly. Second, EDA complexes can often be easily prepared from commercially available reagents, making them readily accessible for usein various reactions. Lastly, EDA complexes can exhibithigh selectivity and efficiency in catalytic reactions, leading to high yields of the desired products.中文回答:催化量的EDA复合物广泛应用于各种化学反应中。
搅拌条件对氢氧化镁混凝性能及絮体特性的影响
2018年第37卷第2期 CHEMICAL INDUSTRY AND ENGINEERING PROGRESS·761·化 工 进展搅拌条件对氢氧化镁混凝性能及絮体特性的影响肖淑敏1,2,赵建海1,2,魏磊1,2,池勇志1,2(1天津城建大学环境与市政工程学院,天津 300384;2天津市水质科学与技术重点实验室,天津 300384) 摘要:通过氯化镁在碱性条件下经搅拌生成氢氧化镁处理活性橙染料模拟配水,研究了搅拌条件对氢氧化镁混凝性能和絮体特性的影响。
以絮凝指数FI 与zeta 电位为考察指标,对絮体形成机理进行了探讨,并对絮体形貌进行观察,旨在揭示絮体形成过程与絮凝效果的关系。
结果表明,延长快速搅拌时间有利于絮体形成,以搅拌45s 为最佳,再延长则会导致絮体被打碎,脱色处理效果变差;慢速搅拌时间以3min 为最佳,过长也会导致絮体破碎。
在最佳搅拌时间基础上发现搅拌速度也是影响混凝性能和絮体特性的主要因素。
快搅或慢搅搅速过低,则不利于形成絮体或絮体增长;若搅速过高,形成的絮体会被打碎,这些都使得脱色处理效果变差。
实验条件下,在Mg 2+计投加量为150mg/L 时,以转速250r/min 或速度梯度G 值126.3,快速搅拌45s ,之后转速60r/min 或G 值18.5,慢速搅拌3min ,氢氧化镁混凝性能最佳,可充分发挥其吸附、电性中和、卷扫与网捕作用,对活性橙染料配水的色度去除率达到95%以上。
关键词:氢氧化镁;活性染料废水;搅拌;混凝;絮体中图分类号:X703.1 文献标志码:A 文章编号:1000–6613(2018)02–0761–06 DOI :10.16085/j.issn.1000-6613.2017-0961Effects of mixing on magnesium hydroxide coagulation performance andfloc propertiesXIAO Shumin 1,2,ZHAO Jianhai 1,2,WEI Lei 1,2,CHI Yongzhi 1,2(1School of Environmental and Municipal Engineering ,Tianjin Chengjian University ,Tianjin 300384,China ;2TianjinKey Laboratory of Aquatic Science and Technology ,Tianjin 300384,China )Abstract :The effect of mixing conditions on the coagulation performance and floc properties of magnesium hydroxide was studied by the reaction of magnesium chloride in an alkaline condition and treatment of simulated reactive orange dyes wastewater. Based on the flocculation index (FI )and the zeta potential ,the mechanism of floc formation was discussed ,and the floc morphology was observed to reveal the relationship between floc formation process and coagulation performance. The results showed that the rapid mixing time is favorable for floc formation ,and the optimum time is 45s. While longer rapid mixing time will result in floc broken and poor treatment effect. Similarly ,the best slow mixing time is 3min. Prolong mixing time will lead to floc broken. Using the optimum mixing time ,it was found that the mixing speed was also the main factor affecting the coagulation performance and floc properties. Lowering rapid and slow mixing speeds are not conducive to the formation and growth ,respectively. However ,higher mixing speed will make the floc broken and consequently reduce the treatment efficiency. When dosage of Mg 2+ is 150mg/L under laboratory conditions ,the optimum conditions for the coagulation performance of magnesium hydroxide were as follows :rapid第一作者:肖淑敏(1979—),男,博士,副教授,研究方向为水污染控制。
多系统器官衰竭(英文)
gastrointestine
stress ulcer and intestinal paralysis: hematemesis呕血 hematochezia 便血 abdominal distention weak bowel sounds gastroscope
liver
acute hepatic failure : jaundice mind abnormal hepatic encephalopathy abnormal biochemical liver function tests : bilirubin↑, transaminase↑
secondary: tardy, after an initial organ dysfunction
and a steady period, another or more organ(s) dysfunction occur(s) secondarily.
It is a consequence of the host response, which result in an inflammatory response in organ distant from the site of the initial insult.
MODS is an important reason for the death of
severe patient.
The Evolution of MODS
In World War I, injured soldiers died in the battlefield of
profound cardiac failure. This was presumed to be caused by wound toxins, but clinical interventions were largely undefined.
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Chemical Engineering and Processing44(2005)461–470Electro-coagulation of reactive textile dyes and textile wastewaterA.Alinsafia,b,M.Khemis a,M.N.Pons a,∗,J.P.Leclerc a,A.Yaacoubi b,A.Benhammou c,A.Nejmeddine da Laboratoire des Sciences du G´e nie Chimique,CNRS-ENSIC-INPL,1,rue Grandville,BP451,F-54001Nancy Cedex,Franceb D´e partement de Chimie,Semlalia Faculty of Sciences,Cadi Ayyad University,Boulevard Prince Moulay Abdellah,BP2390,40000Marrakech,Moroccoc Laboratoire d’Automatique et d’Etudes des Proc´e d´e s,Semlalia Faculty of Sciences,Cadi Ayyad University,Boulevard Prince Moulay Abdellah,BP2390,40000Marrakech,Moroccod D´e partement de Biologie,Semlalia Faculty of Sciences,Cadi Ayyad University,Boulevard Prince Moulay Abdellah,BP2390,40000Marrakech,MoroccoReceived20November2003;received in revised form17February2004;accepted10June2004Available online25August2004AbstractElectro-coagulation of a blue reactive dye(Drimarene K2LR CDG Blue)solution has been optimised by experimental design and surface response analysis in terms of colour removal and chemical oxygen demand(COD)decrease.The optimal conditions(pH,current density,reac-tion time)have then been applied to other reactive dyes solutions as well as synthetic and real textile wastewater samples.The biodegradability before and after electro-coagulation has been assessed by short-term respirometry and is increased by this type of treatment.©2004Elsevier B.V.All rights reserved.Keywords:Electro-coagulation;Reactive dye;Colour removal;Experimental design;Biodegradability1.IntroductionWastewater from textile dyeing andfinishing factories is a significant source of environmental pollution[1].Reactive dyes are extensively used in textile industry,fundamentally due to the ability of their reactive groups to bind to textile fibres by covalent bonds formation[2].These characteristics facilitate the interaction with thefibre and reduce energy con-sumption[3].The major environmental problem associated with the use of the reactive dyes is their loss in the dyeing process.Thefixation efficiency is in the range60–90%[3]. Consequently,substantial amounts of unfixed dyes are re-leased in wastewater.Textile wastewater is characterized by high chemical oxygen demand(COD),low biodegradability, high-salt content and is the source of aesthetic pollution re-lated to colour.EU directive91/271imposes limits on colour, as it reduces light penetration in receiving water bodies.∗Corresponding author.Tel.:+33383175277;fax:+33383175326.E-mail address:marie-noelle.pons@ensic.inpl-nancy.fr(M.N.Pons).A wide range of wastewater treatment techniques have been tested.Biological processes(aerobic and anaerobic) [4–6]are probably the most inexpensive ones but dyes are inhibiting bacterial development[7].A pre-treatment is of-ten necessary to increase the biodegradability.A large range of physico-chemical processes have been proposed:coag-ulation with alum,ferric chloride,magnesium chloride and lime or polymers[4],adsorption on activated carbon,polymer and mineral sorbents or biosorbents[8,9],chemical oxidation [1,10,11],photolysis[11,12],suspended[13,14]or supported photocatalysis[15],electrophotocatalysis[16]but,except in the two last cases,they require the addition of chemicals.Electro-coagulation has been successfully used to treat a variety of industrial wastewaters[17–22].The goal is to form flocs of metal hydroxides within the effluent to be cleaned by electro-dissolution of soluble anodes.Three main processes occur during electro-coagulation:electrolytic reactions at the surface of electrodes,formation of coagulants in aqueous phase,adsorption of soluble or colloidal pollutants on co-agulants,and removal by sedimentation andfloatation.The0255-2701/$–see front matter©2004Elsevier B.V.All rights reserved. doi:10.1016/j.cep.2004.06.010462 A.Alinsafiet al./Chemical Engineering and Processing44(2005)461–470main reactions at the electrodes are:Al→Al3++3e−(at anode)(1) 3H2O+3e−→32H2+3OH−(at cathode)(2) The destabilized particles then aggregate to formflocs.In the meantime,the tiny hydrogen bubbles produced at the cath-ode induce thefloatation of mostflocs,helping to effectively separate particles from wastewater.In addition,the cathode may be chemically attacked by OH−ions generated together with H2at high pH values[23]. 2Al+6H2O+2OH−→2Al(OH4)−+3H2(3) Al(aq)3+and OH−ions generated by electrode reactions(1) and(2)react to form various monomeric species which trans-formfinally into Al(OH)3according to complex precipitation kinetics[24].Several interaction mechanisms are possible be-tween dye molecules and hydrolysis by-products.Two major mechanisms are generally considered:precipitation(for pH lower than6.5)and adsorption(for higher pH)[24,25].Precipitation:Dye+monomeric Al→[Dye-monomeric Al](s)pH4–5(4)Dye+polymeric Al→[Dye-polymeric Al](s)pH5–6(5)Adsorption:Dye+Al(OH)3(s)→→[particle](6) [Dye-polymeric Al](s)+Al(OH)3(s)→→→[particle](7) Theseflocs polymerise as:n Al(OH)3→Al n(OH)3n(8) Compared with traditionalflocculation and coagulation, electro-coagulation has,in theory,the advantage of removing small colloidal particles;they have a larger probability of be-ing coagulated because of the electricfield that sets them in motion.Addition of excessive amount of coagulants can be avoided,due to their direct generation by electro-oxidation of a sacrificial anode.Electro-coagulation equipment is simple and easy to operate.Short reaction time and low sludge pro-duction[26]are two other advantages of the technique.There are,however,several parameters such as size,shape and dis-tance between electrodes,current density,conductivity,pH, reaction time that should be selected with care to optimise the process efficiency.G¨u rses[24]have investigated the effect of electrode nature,mixing,cell voltage,electrolysis time and current density on aqueous solutions of reactive dyes.The present study aims at evaluating the influence of the key process variables such as current density,electrolysis time and initial pH on the efficiency of treatment(or pre-treatment)of textile wastewater containing reactive dyes. Textile wastewater exhibit usually high pH and contains large amounts of substances such as sizing agents,surfac-tants,volatile organic compounds,salts that can interfere with electro-coagulation.The experiments were carried out according to a23full factorial experimental design.Then, the process was optimised according to a22factorial exper-imental design to improve the efficiency of decolourisation and the abatement of organic matter.Finally the effect of electro-coagulation performed under optimal conditions on the biodegradability of the effluents has been investigated.2.Materials and methodsAluminum(composition:C:0.45–0.5%;Mn:0.5–0.8%; Si:0.4%;Al:98.3–98.61%)flat electrodes of rectangular shape(height=100mm;width=50mm and distance be-tween electrodes=20mm)were used in a100ml electro-coagulator made out of Pyrex glass.The solution to be treated is stored in a magnetically stirred reservoir.The experimental set-up is given in Fig.1.Sodium chloride was added in all runs so to have a conductivity of the solution of4.7mS/cm.Cell voltage and current were measured by digital voltmeter and ampmeter,respectively.The solution(total volume=500ml) was continuously circulated in the system with the help of a peristaltic pump at aflowrate of370ml/min.This corre-sponds to a Reynolds number of about220in the reaction chamber.Theflow regime is laminar and favours the growth of largeflocs that are easier to remove.The current efficiency(φ)for the production of dissolved Al3+was calculated by comparison of the weight loss of the aluminium electrodes during the experiment( m exp)with the theoretical amount of aluminium consumed according to Faraday’s law( m theo).φ=m expm theo(9) where m theo=ItM Al/3F with I(A)is the current intensity, t(s)the experiment duration,M Al(g/mol)the molar mass of aluminium and F the Faradayconstant.Fig.1.Experimental set-up.1:DC power supply,2:Digital Ampermeter, 3:Digital V oltmeter,4:Anode and cathode,5:Sample of wastewater,6: Peristaltic pump,7:Magnetic stirring controller.A.Alinsafiet al./Chemical Engineering and Processing 44(2005)461–470463The specific electrical energy consumption (seec)was cal-culated as a function of the applied cell voltage (U in volts)[27].seec (kWh /kg Al)=3FU3.6×10M Al φ(10)Solutions of reactive textile dyes (at a concentration of 50mg/l)were prepared by dissolution in de-ionised water of Drimarene (Clariant,Mutenz,Switzerland)K2LR CDG Blue,Drimarene Black and Yellow Procion Hexl (Dys-tar,Frankfurt,Germany).Synthetic textile wastewater was obtained by dissolution of hydrolysed reactive dyes (Dri-marene K2LR CDG Blue (2.78mg/l);Drimarene KG Orange (3mg/l);Drimarene K8B CDG Red (24.3mg/l)),hydrolysed starch (2.78mg/l),(NH 4)2SO 4(5.56mg/l)and Na 2HPO 4(5.56mg/l)in de-ionised water.Hydrolysis was performed by heating the solutions at 80◦C for 1.5h after adjustment at pH 12.Synthetic textile wastewater pH was adjusted at 10and conductivity at 4.7mS/cm.Two real textile wastewater samples from a knit cotton factory (Marrakech,Morocco)(global effluent),which is using the same type of dyes were also tested.Dyes concentrations were estimated from their absorbance characteristics in the UV–vis range (200–800nm).A SECO-MAM (Domont,France)Anthelie Light spectrophotometer connected to a PC was used.Each dye is associated to a main absorbance band at a characteristic wavelength:in the con-centration range used throughout this study,linear relations between dye concentration and absorbance at the dye charac-teristic wavelength were obtained.Dissolved organic carbon (DOC)measurements were carried out on an APOLLO 9000total organic carbon analyser after filtration (10m).Chem-ical oxygen demand (COD)was measured on a Hach 2400(Loveland,Colorado,USA)(Method 8000).pH and conduc-tivity were measured using respectively a PHM 220pHmeter and a CDM 210conductimeter (Radiometer Analytical SAS,Villeurbanne,France).To compare the efficiency of electro-coagulation with re-spect to wastewater biodegradability short-termrespirometryFig.2.Typical protocol of biodegradability analysis by respirometry.batch tests were performed [28].Activated sludge (1.6l )from the local domestic wastewater treatment plant was placed into the 2l-respirometer,equipped with an air-sparger and a mechanical stirrer.The dissolved oxygen concentration was monitored with Orbisphere (Marin,Switzerland)electrodes connected to a PC for data logging.Activated sludge was suc-cessively spiked with a sodium acetate solution,which acts as a reference carbon source,the wastewater sample to be tested and again the sodium acetate solution (Fig.2).The dissolved oxygen (S 0)mass balance in the liquid phase is given by:d S 0d t=K L a (S ∗0−S 0)−OUR exo −OUR end (11)where S ∗0is the dissolved oxygen concentration at saturation,K L a is the oxygen mass transfer coefficient,OUR end ,the oxygen uptake rate for slowly biodegradable substances and OUR exo the oxygen uptake rate for rapidly biodegradable substances.When recalcitrant and/or toxic substances (with respect to the activated sludge bacteria)are present in the wastewater sample,the oxygen uptake rates decrease.The respirograms were characterized by the maximal value taken by OUR (OUR max )and the volume of oxygen consumed for 20min after the injection of the wastewater sample.Fig.2presents a typical respirogram.3.Experimental designStatistical calculations were done using NEMRODW ver-sion 2000(LPRAI,Marseille,France).In a first stage,the effect of three electrochemical variables (current density,electrolysis time and initial pH of the solution)on the de-colourisation was investigated according to a 23full factorial experimental design with five replicates of the centre point.Before statistical analysis,the original variables X 1(elec-trolysis time),X 2(current density)and X 3(initial pH of the solution)were reduced.The levels for the three main vari-ables were chosen from previous know-how.The original and reduced levels are given in Table 1.464 A.Alinsafiet al./Chemical Engineering and Processing44(2005)461–470 Table1Original and reduced levelsParameters Originalvariable(X)Reduced variable(x)−10+1Electrolysis time(min)X16090120 pH X278.510 Current density(mA/cm2)X3102540 The choice of pH in the range7–10is on one hand due to the good efficiency of the electrocoagulation treatment at pH between4and9with aluminium electrodes[19,29,30]and on the other hand to the alkaline character of the real textile wastewater discharged on the industrial site related to the present study.The choice of an electrolysis time in the range 60–120min may appear large compared to what is described in literature.It is due mainly to the important sample volume (500ml)compared to the capacity of cell(100ml).In a second stage,the main objective was to select the current density and the electrolysis time in order to achieve optimal COD removal and decolourisation.We considered a22Doehlert matrix for investigating the effect of current density and electrolysis time,while the initial pH of the so-lution was set to10,as this value is close to the real textile wastewater pH.Uniform Doehlert networks were generated from a Simplex(Table2).4.Results and discussion4.1.Decolourisation kineticsColour is effectively removed by electro-coagulation,as depicted in Fig.3for a solution of Drimarene K2LR CDG Blue.A global decrease of the UV–vis absorbance is ob-served.Simultaneously DOC decreases.DOC abatement in this case is about46%and can reach up54%in some exper-iments.4.2.Statistical analysis and modellingThe objective is to provide a predictive model able to explain the influence of operational parameters on product quality.The dimension of the model is very much reduced compared to the dimension of the concerned data group.The results obtained for the23full factorial design are given in Table3for Drimarene K2LR CDG Blue,which decolourisa-tion yield varies between72and98%(average value92%). Table2The coordinates of the initial SimplexNumber X1(electrolysis time)X2(current density) 10021030.50.866Fig.3.Absorbance spectra(A)and kinetic curves of colour and dissolved organic carbon(B)of Drimarene K2LR CDG Blue dye vs.reaction time for an initial pH10and current density=10mA/cm2.The experimental error(2.8%)due to uncontrolled factors is calculated from the replicates of the centre point.The decolourisation yield(Y1)can be predicted by Eq.(12)using the coefficients listed in Table4.Y1=b0+b1X1+b2X2+b3X3+b12(X1X2)+b13(X1X3)+b23(X2X3)+b123(X1X2X3)(12) From the experimental values taken by the Student coeffi-cient t exp,an experimental significance level is calculated. b0,b1and b3are significant at a level less than5%,when the interaction coefficient b13is significant at a level less than 10%.Therefore the reaction time(coefficient b1),the cur-rent density(coefficient b3)and their interaction(coefficient b13)are the most influential factors.In fact,the decolourisa-tion is occurring by adsorption[25]on Al(OH)3(s)or on the monomeric anion Al(OH)4−depending upon the dye chemi-cal structure,which is unfortunately unknown for most com-mercial dyes.In the present case no adjustment is needed for pH:on the contrary to what is observed for the current density and the reaction time,its significance level is very high(85%), which means that pH is not an influential parameter.The ef-fects of operational variables on process performance may be explored with wastewater as discharged from the textile dyeing plant.The analysis of variance(Table5)shows thatA.Alinsafiet al./Chemical Engineering and Processing44(2005)461–470465 Table323full factorial design with5repetitions of the centre pointRun x1(electrolysis time)x2(initial pH)x3(current density)Y1(decolourisation)(%) 1−1−1−172.1621−1−197.833−11−180.58411−188.185−1−1194.1361−1194.647−11196.26811196.26900095.541000095.141100094.661200094.351300098.41Table4Model coefficientsCoefficient Value Standarddeviation t exp Significancelevel(%)b092.1651.28671.64<0.01b14.2231.6402.574.92b20.3151.6400.1984.9b35.3171.6403.242.31b12−2.3221.640−1.4221.5b13−4.0951.640−2.505.4b230.6231.6400.3871.8b1232.1951.6401.3423.8the predictive model insured a representativity of the experi-mental data of about92%,as the significance level calculated from the ratio of the mean square errors due to the regression and to the residues is7.7.4.3.Process optimisationThe surface response methodology helps to develop a sta-tistical model of a reaction by performing the minimum num-ber of well-chosen experiments and to determine the optimal values of process parameters.This approach is particularly suitable when a given variable depends on the settings of an-other one(interaction effects).This methodology is here ap-plied to the decolourisation yield and the abatement of COD. The considered factors are the current density in the cell and the electrolysis time.A22full factorial design with three replicates of the centre point(Table6)was applied.Figs.4and5show the contour plots obtained from the lin-ear models built from the experimental results.These plotsTable5Analysis of variance for decolourisation percentageSum of square errors Degrees offreedomMeansquareerrorRatio of meansquare errorsSignificancelevel(%)Regression588784 3.97.7 Residues107521Total69612Table6Doehlert matrixRun X1(electrolysistime)X2(currentdensity)Y1(decolourisation)Y2(CODremoval) 11097.7716.222−1094.79+16.22 30.50.86697.2311.364−0.5−0.86693.8027.27 50.5−0.86690.9836.366−0.50.86696.0713.64 70.094.6618.18 80094.3516.22 90098.4112.12Table7Coefficients of the predictive model of Y1(%decolourisation)Coefficient Value Standarddeviationt exp Significancelevel(%)b095.807 1.23877.36<0.01b10.717 1.2380.5860.5b22.460 1.2381.9914.0b110.473 1.9580.2481.7b22−1.873 1.958−0.9641.1b122.298 2.4770.9342.4were obtained by calculating the coefficients of Eq.(13) and drawing subsequently the contour for the electrolysis time—density current variable pair for Y1(Table7)and Y2 (Table8):Y=b0+b1X1+b2X2+b11X12+b22X22+b12X1X2(13)Table8Coefficients of the predictive model of Y2(%COD removal)Coefficient Value Standarddeviationt exp Significancelevel(%)b015.507 1.7278.980.212b11.135 1.7270.6656.0b2−11.152 1.727−6.460.622b110.713 2.7310.2680.4b228.631 2.7313.164.95b12−6.565 3.455−1.9015.3466 A.Alinsafiet al./Chemical Engineering and Processing 44(2005)461–470Fig.4.Two dimensional contour plot obtained from the experimental data of COD removal vs.electrolysis time (X 1)and current density (X 2).Fig.4shows that COD removal is maximal in the region where the electrolysis time is between 90and 120min and for a current density of about 12mA/cm 2.In fact,when the current density increases,there are an increase of the amount of aluminium dissolved in the liquid phase and an increase of the production of hydroxide Al(OH)3.For long electrolysis times,the structure of the sludge may change,altering the efficiency of pollution removal and the settle-ability and float-ability properties of the flocs.In Fig.5,the decolourisation yield is up to 98%in the global experimental plan:highvalues Fig.5.Two dimensional contour plot obtained from the experimental data of decolourisation yield vs.current (X 2)and electrolysis time (X 1).of both variables maximize the decolourisation yield due to the good adsorption of dye on sludge.The objective is to determine the optimal pair current density—electrolysis time to achieve both a good decolouri-sation yield and a good abatement of organic matter expressed as COD.Several scenarios can be examined in order to find the optimal conditions.The objectives for each scenario are transformed into functions d i ,which give the percentage of satisfaction obtained with respect to the fullfillness of the tar-gets that have been set in terms of decolourisation and CODA.Alinsafiet al./Chemical Engineering and Processing44(2005)461–470467Fig.6.Desirability function.removal(Fig.6).The values of d i are combined in a geometric mean:D=(d1×d2···d m)1/mwith m is the number of functions d i involved in the compu-tation of the total desirability D to be optimised.A minimal efficiency in terms of decolourisation(90%)and COD re-moval(30%)is required.Two scenarios were tested(Table9).In Scenario1,the target for decolourisation was set at95%and for COD re-moval at36%.In Scenario2,the target for decolourisation was increased but the target for COD was decreased.In both cases,COD removal targets are almost reached but colour removal cannot be achieved as efficiently as expected.To select between both scenarios,another criterion should be incorporated.It could be the cost of electrodes or the energy consumption.Energy consumption could be estimated by the product X1×X2.In the present case Scenario1was preferred for its lower energy requirement.The optimum is obtained for X1= 105min and X2=12mA/cm2that insures92%on decolouri-sation and35%on COD removal.It is characterised by an average desirability about55.3%and maximum desirability about88.3%as shown in Table10.In this case,the specific electrical energy consumption is about13.5kWh/kg Al and the apparent current efficiency is around1.1,slightly above1 as in the experiments of Jiang et al.[27],who explained such a discrepancy by the occurrence of secondary reactions.Table9Optimal sets for the two scenariosScenario1Scenario2Minimum Target Minimum Target Decolourisation(%)90959098 COD removal(%)30363035 Optimal electrolysistime(min)104.95105.68Optimal currentdensity(mA/cm2)1212.21Y1,theor91.7391.82Y2,theor35.2735Table10Characteristics of optimal pair(D=desirability)Response Value D(%)Weight D min(%)D max(%) Y1(decolourisation)91.753510.078Y2(COD removal)35.2387137.3100 Global desirability55.3088.3 4.4.Treatment efficiency at optimal conditionsThe optimal electro-coagulation conditions found in the previous section(electrolysis time=105min and current den-sity=12mA/cm2)were applied to other reactive dyes as well as synthetic and industrial textile wastewater samples. In industrial environment it is difficult to determine the opti-mal values of the operation parameters,as the characteristics of the wastewater are changing daily in function of the tex-tile production program.The results show that the electro-coagulation efficiency differs very much according to the dyes.For the blue dye the experimental responses Y1and Y2 (Table11)are close to the theoretical ones(Table9)ob-tained by the desirability study and validate the choice of the electrolysis time and the current density.For the two simple dye solutions(Yellow Procion and Drimarene Black)high COD removal yields were achieved,in spite of very different initial COD concentration.High decolouri-sation yields were also observed.In the case of the syn-thetic wastewater,COD removal was medium in spite of a low initial COD concentration.This synthetic wastewa-ter attempts to mimic the effect of textile dyeing,which is performed at a relatively high temperature,on the dyes and other additives(starch,salts).The two industrial wastewa-ter samples have higher initial COD than the other tested solutions.However the electro-coagulation remains very ef-ficient with respect to COD removal and decolourisation. Those two samples were collected on two successive days, giving another example of the high variability degree of tex-tile wastewater.In any case large variations of DOC are also observed.4.5.Biodegradability assessmentTo estimate the level of biodegradability of textile wastew-ater by the activated sludge before and after the electro-coagulation treatment,batch respirometry tests with activated sludge have been performed.Table12shows a summary of the estimated parame-ters.K L a and OUR end were calculated for each experi-ment.Depending upon the type of sample,the observed behaviour differed.The Drimarene Black sample was slightly biodegradable before electro-coagulation as shown in Fig.7a by the reduced oxygen uptake rate in spite of a high COD(255mg/l).Its biodegradability increased after electro-coagulation,which decreases also strongly its COD content. For Textile I wastewater much larger values of oxygen uptake468 A.Alinsafiet al./Chemical Engineering and Processing 44(2005)461–470Table 11Efficiency of treatment at optimal conditions (COD 0=initial solution COD)SampleDOC removal (%)Y 2(%COD removal)Y 1(%decolourisation)Drimarene Blue DR K2LR CDG (COD 0=154mg O 2/l)72.838.290.7Yellow Procion hexl (COD 0=95mg O 2/l)61.688.292.6Drimarene Black (COD 0=255mg O 2/l)18.681.394.3Real wastewater I (COD 0=450mg O 2/l)22.865.283.3a Real wastewater II (COD 0=620mg O 2/l)34.274.898.6a Synthetic wastewater (COD 0=70mg O 2/l)51.276.083.9aAverage value at three wavelength 620,525and 436nm.rates were observed before than after electro-coagulation (Fig.7b),although this treatment decreases strongly also the COD content.Finally in the case of Textile II wastewater,almost no change can be seen in the respirometry patterns (Fig.7c).Similar behaviours occurred for the yellow and the blue dyes solutions as well as for the syntheticwastewater.Fig.7.Oxygen uptake rate vs.time for (a)Drimarene Black solution,(b)Textile I wastewater and (c)Textile II wastewater,before and after electro-coagulation.To conclude about an eventual biodegradability improvement after pre-treatment the biodegradability yield is calculated as:Y B =(V O 2/COD)after electro-coagulation (V O 2/COD)before electro-coagulationA.Alinsafiet al./Chemical Engineering and Processing44(2005)461–470469 Table12Summary of the estimated parameters during respiromety testsBefore electro-coagulation After electro-coagulation Y BOUR exomax(mg/l/s)V O2(mg/l)OUR exomax(mg/l/s)V O2(mg/l)Yellow Procion hexl0.00523.00.0055 3.09 Drimarene K2LR CDG Blue0.00463.30.0043 2.51.5 Drimarene Black0.00372.0.0066 2.99.5 Synthetic textile wastewater0.00543.10.0054 3.24.4 Textile wastewater I0.01613.80.013 6.52 Textile wastewater II0.00950.009 4.24In all tested cases,an increase of the biodegradability was observed but,as for COD and colour removal efficiency,it depends very much upon the sample composition.5.ConclusionsElectro-coagulation is an efficient process,even at high pH,for the removal of colour and total organic carbon in reactive dyes textile wastewater.The efficiency of the pro-cess is influenced strongly by the current and the time of the reaction.Optimal electrolysis time and current density were de-termined to achieve a decolourisation yield between90and 95%and COD removal between30and36%for a reactive blue dye.Although these operational parameters were ap-plied to other reactive dyes solutions as well as synthetic and real textile wastewater and led to satisfactory colour removal and increase of biodegradability,the effect of the wastewater nature,which is highly time-variable in an industrial envi-ronment,could be pointed out.AcknowledgementsThe authors are thankful to the textile industry Tenmar and to the French-Moroccan Committee(project MA/02/49). They wish also to thank Professor J.P.Corriou for his helpful comments.References[1]E.G.Solozhenko,N.M.Soboleva,V.V.Goncharut,Decolourizationof azo dye solutions by Fenton’s oxidation,Water Res.29(1995) 2206–2210.[2]J.Weber,V.C.Stickney,Hydrolysis kinetics of reactive Blue19-vinylsulfone,Water Res.27(1993)63–67.[3]R.Camp,P.E.Sturrock,The identification of the derivatives ofCI reactive Blue19in textile wastewater,Water Res.24(1990) 1275–1278.[4]M.T.Kennedy,J.M.Morgan,L.K.Benefield,A.F.McFadden,Colorremoval from textile dye wastewater:a case study,in:Proceedings of the47th Ind.Waste Conference,West Lafayette,IN,Lewis Pub, Chelsea,MF,1992,pp.727–741.[5]Y.K.Park, C.H.Lee,Dyeing wastewater treatment by activatedsludge process with a polyurethanefluidised bed biofilm,Water Sci.Technol.34(5–6)(1996)193–200.[6]C.B.Shaw,C.M.Carliell,A.D.Wheatley,Anaerobic/aerobic treat-ment of coloured textile effluents using sequencing batch reactors, Water Res.36(2002)1193–2001.[7]D.Georgiou,P.Melidis,A.Aivasidis,Use of a microbial sensor:inhibition effect of azo-reactive dyes on activated sludge,Bioprocess Biosyst.Eng.25(2002)79–83.[8]T.Robinson,B.Chandran,P.Nigam,Removal of dyes from a syn-thetic textile dye effluent by biosorption on apple pomace and wheat straw,Water Res.(2002)36.[9]A.Pala,E.Tokat,Color removal from cotton textile industry wastew-ater in an activated sludge system with various additives,Water Res.36(2002)2920–2925.[10]S.F.Kang,H.M.Chang,Coagulation of textile secondary effluentswith Fenton’s reagent,Water Res.36(12)(1997)215–222. [11]M.P´e rez,F.Torrades,X.Dom`e nech,J.Peral,Fenton and photo-Fen-ton oxidation of textile effluents,Water Res.36(2002)2703–2710.[12]W.Chu,S.M.Tsui,Modeling of photodecoloration of azo dye in acocktail photolysis system,Water Res.36(2002)3350–3358. [13]B.Zielinska,J.Grzechuslka,A.W.Morawski,Photocatalytic decom-position of textile dyes on TiO2Tytanpol Al1and TiO2-Degussa P25, J.Photochem.Photobiol.A Chem.157(1)(2003)65–70.[14]B.Neppolian,S.Sakthivel,B.Arabindoo,V.Murugesan,Solar/UV-induced photocatalytic degradation of three commercial textile dyes, J.Hazard.Mater.89(2002)303–317.[15]C.Hachem,F.Bocquillon,O.Zahraa,M.Bouchy,Decolourizationof textile ionudstry wastewater byt the photocatalytic degradation process,Dyes Pigments49(2001)117–125.[16]M.V.B.Zanoni,J.Sene,M.A.Anderson,Photoelectrocatalytic degra-dation of Remazol Brilliant Orange3R on titanium dioxide thin-film electrodes,J.Photochem.Photobiol.A Chem.157(1)(2003)55–63.[17]E.Dobolyi,Experiments aimed at the removal of phosphate by elec-trochemical methods,Water Res.12(1978)1113–1116.[18]L.M.Balmer,A.W.Foulds,Separation oil from oil-in water emul-sions by electroflocculation/electroflotation,Filtr.Sep.23(1986) 366–369.[19]J.S.Do,M.L.Chen,Decolorization of dye-containing solutions byelectrocoagulation,J.Appl.Electrochem.24(1994)785–790. [20]S.H.Lin, C.F.Peng,Continuous treatment of textile wastewaterby combined coagulation–electrochemical oxidation and activated sludge,Water Res.30(1996)587–592.[21]X.M.Chen,G.H.Chen,P.L.Yue,Separation of polluants fromrestaurant wastewater by electrocoagulation,Sep.Purif.Technol.19 (2000)65–76.[22]X.M.Chen,G.H.Chen,P.L.Yue,Electrocoagulation and electroflo-tation of restaurant wastewater,J.Environ.Eng.126(2000)858–863.[23]T.Picard,G.Cathalifaud-Feuillade,M.Mazet,C.Vandensteendam,Cathodic dissolution in the electrocoagulation process using alu-minium electrodes,J.Environ.Monit.2(2000)77–80.[24]A.G¨u rses,M.Yalc¸in,C.Do˘g an,Electrocoagulation of some reactivedyes:a statistical investigation of some electrochemical variables, Waste Manage.22(2002)491–499.[25]M.Rebhun,M.Lurie,Control of organic matter by coagulation andfloc separation,Water Sci.Technol.27(1993)1–20.。